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ABSTRACT 
 
Signaling pathways that respond to stress and sense nutrient availability are highly conserved throughout 
eukaryotes.  In mammalian cells, these pathways have evolved to regulate immune responses, 
representing important therapeutic targets. Interestingly, components of these pathways can be found in 
plants, yeast and nematodes, where they also participate in response to abiotic and biotic stress. The 
Amino Acid Response (AAR) pathway, an ancient response to the cellular accumulation of uncharged 
tRNA, is part of the larger Integrated Stress Response (ISR) in mammals.  The ISR consists of multiple 
branches, each one triggered by distinct stresses that produce phospho-eIF2α signal generation. Each ISR 
initiating stress results in a unique cellular response due to activation of both the ISR and additional 
parallel pathway(s) by the initiating stress, but, to date, no such alternate pathway has been identified for 
the AAR pathway.  Despite its integral role in stress adaptation, the ISR has not been studied in early 
diverging animals.  I have identified a highly conserved phosphorylation site in the protein eIF2α, the 
signature ISR effector, which allowed me to use a mammalian antibody to identify and characterize the 
ISR in the basal metazoan, Nematostella vectensis, revealing that the core components of the mammalian 
ISR were present over 550 million years ago in the common ancestor of cnidarians and bilaterians. 
Additionally, our lab has discovered a novel branch of the AAR pathway that regulates key tissue 
protective signals. Using evolutionary conservation of this pathway in model organisms, I have identified 
GCN1 as the branch point that links the signal generation components of the AAR pathway to 
downstream therapeutic effects. I then used transcriptomic and protein interaction analyses to begin to 
understand the scope of this pathway and identify key pathway regulators. 
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I.  All cells respond to nutrients and stress 
 
All cells have the capacity to sense and respond to factors in their environment, particularly nutrients, 
required to generate the energy and building blocks of the cell.  Cells and organisms must coordinate their 
growth with nutrient availability.  Many nutrient sensing pathways of the cell are also co-opted for 
cellular stress response, mediating adaptive and protective changes not only to nutrients but to other 
abiotic and biotic factors (1-7).  In mammals, these pathways have further evolved functions in immunity 
(8-12).  Many constituents of nutrient and cellular stress response pathways are among the most highly 
evolutionarily conserved genes across all three domains of life (13). Although much of this ancient 
cellular machinery has been studied extensively, some basic components of highly conserved nutrient 
response pathways remain poorly understood.  
 
In eukaryotic cells, two highly conserved pathways are known that sense and respond to intracellular 
amino acid levels, mechanistic Target Of Rapamycin (mTOR)C1 and the Amino Acid Response (AAR) 
pathway.  Both pathways regulate adaptive changes to maintain homeostasis in response to amino acid 
supply.  Interestingly these pathways are key regulators of lifespan in model organisms and both 
pathways regulate immune function in mammalian cells (14-17).  Although both pathways respond to 
amino acid levels, they are differentially activated and regulate distinct cellular programs.  Unlike the 
AAR pathway, the mTORC1 pathway is thought to sense amino acid levels directly and is inhibited by 
amino acid restriction (18).  The AAR pathway, in contrast, is activated by intracellular accumulation of 
uncharged tRNAs that can result from the lack of any amino acid or from inhibition of any aminoacyl-
tRNA synthetase (19).  Uncharged tRNA binds and activates the kinase GCN2, resulting in 
phosphorylation of eIF2α, a shared component of multiple stress response pathways, referred to as the 
Integrated Stress Response (ISR).  Study of the AAR pathway, conserved across eukaryotes, led to the 
discovery of the expanded mammalian integrated stress response (ISR), a group of stress sensing 
pathways that converge on phosphorylation and activation of eIF2α, a master regulator of stress response 
in mammalian and likely all metazoan cells (20, 21). 
 
In this thesis, one goal was to use the high degree of conservation of components of the ISR and AAR 
pathway to determine whether the core mammalian ISR is conserved in the basal metazoan cnidarian, 
Nematostella vectensis. The ISR’s broad conservation within eukaryotes suggests that it likely plays a 
similar role in animals from early diverging lineages such as cnidarians (1, 22).  Although it is clear that 
cnidarians respond to environmental stressors, little is known about the molecular signaling pathways that 
evoke these responses (23, 24). Signaling pathways regulating cellular stress responses have been 
extensively studied in classic model eukaryotes such as yeast, mice, and humans, but few studies have 
explored these pathways in early diverging animal lineages.  In addition, I used the evolutionary 
conservation of the AAR pathway throughout eukaryotes to elucidate an unknown signaling pathway 
triggered by uncharged tRNA observed by our lab in mammalian cells.  Our lab previously solved the 
mechanism of the small molecule therapeutic halofuginone (HF) (Fig 1) by demonstrating that it binds to 
and inhibits the proly-tRNA synthetase (PRS) activity of the fused amino-acyl tRNA synthetase (aaRS) 
glutamyl-prolyl tRNA synthetase (EPRS) (25, 26).  Because HF is a potent inhibitor of PRS, it acts as an 
amino acid restriction mimetic, and, like other aaRS- inhibitors, it triggers the cellular accumulation of 
uncharged tRNAs thereby activating the AAR pathway (25).  Our lab found that in an in vitro system of 
TNFα-stimulated fibroblast-like-synoviocytes (FLS), cells implicated in the pathology of rheumatoid 
arthritis, treatment with either HF or the threonyl-tRNA synthetase inhibitor, borrelidin, suppresses a pro-
inflammatory transcriptional program in these cells (Kim et al, manuscript in preparation).  Likewise, our 
scientific collaborator Mark Sundrud has found that HF or borrelidin treatment inhibits in vitro 
differentiation and proliferation of pro-inflammatory Th17 cells (27).  Our lab and the Sundrud lab further 
made the key observation that these downstream inflammatory suppressive effects triggered by uncharged 
tRNA occurs in cells that lack the signature AAR pathway effector, GCN2.  GCN2 is considered the sole 
sensor of uncharged tRNA in the eukaryotic cell, but these data suggest there is an undescribed 
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mammalian signaling pathway that responds to amino acid limitation, and an unknown sensor of 
uncharged tRNA. 
 
II.  All cells have evolved mechanisms to sense stress through the translational apparatus 
 
Translation is an expensive process regulated in all cells 
All cells regulate protein translation.  From microbes to higher organisms the availability of amino acids 
either endogenously synthesized or acquired from the environment is necessary for survival (28).  Amino 
acids are the building blocks of proteins, which are essential for the structure, function, and regulation of 
the cell; however, protein synthesis is an energetically expensive process, using 22-30% of a cell’s total 
energy (3, 29).  Failure to finish peptide chain synthesis due to stalled ribosomes under amino acid 
scarcity is energetically inefficient and cells primarily regulate translation at the initiation step (29, 30).  
To keep translation in tune with cellular conditions, all cells have evolved mechanisms to sense stress 
through the translational apparatus. 
 
III.  The Bacterial Stringent Response (Fig 2) 
 
The bacterial stringent response is a paradigm of stress response, which results in massive transcriptional 
reprogramming (31).  Upon amino acid deprivation, stalled ribosomes containing uncharged tRNA at the 
A-site accumulate.  The enzyme, RelA detects and binds uncharged tRNA and stalled ribosomes at the A-
site, where RelA then synthesizes a hyper phosphorylated guanine analogue, (p)ppGpp, from GTP/GDP 
and ATP (31).  ppGpp acts as a master regulator of gene transcription, upregulating adaptive genes like 
amino acid biosynthetic genes to counteract low amino acid levels and protective or defensive genes like 
virulence factors.  ppGpp directly regulates transcription by binding the RNA polymerase core enzyme.  
In addition, ppGpp binds bacterial initiation factor 2, decreasing its binding to fMet-tRNAfMet, 
downregulating protein translation to conserve energy (31-34).  ppGpp not only increases during amino 
acid starvation, but also in response to other types of nutrient limitation and factors causing growth arrest 
(32).  The stringent response plays an important role in antibiotic resistance and survival of pathogenic 
bacteria under stress.  The stringent response has been found in bacteria and plant plastids, but not in 
archaea, yeast, or animals (32, 35, 36).  ppGpp has not been found in archaea, but an eIF2α kinase 
homolog has been identified (37, 38).   
 
IV.  The Eukaryotic Amino Acid Response (AAR) Pathway 
 
Although the stringent response has not been found in eukaryotes, other than plant plastids, a eukaryotic 
pathway that shares the hallmarks of the stringent response is the AAR pathway, in which uncharged 
tRNA signals amino acid depletion at the ribosome resulting in translational inhibition and adaptive and 
protective gene expression.  The AAR pathway was first discovered in yeast over 40 years ago, in which 
it was observed that a large number of genes encoding enzymes in multiple amino acid biosynthetic 
pathways were under common control (39, 40). In Saccharomyces cerevisiae, starvation for an amino 
acid or the presence of a defective aminoacyl-tRNA synthetase leads to increased transcription of more 
than 30 genes encoding amino acid biosynthetic genes.  Since this response leads to enhanced 
transcription of amino acid biosynthetic genes from several different amino acid biosynthetic pathways, 
the response was called the general amino acid control (GAAC) (40).  Genetic analyses identified several 
trans-acting positive factors required for the GAAC including general control nonderepressible or GCN1, 
GCN2, GCN3, and GCN4 that constitute the major components of the AAR pathway (40). 
 
The AAR Pathway: the GCN2-eIF2α-ATF4 pathway (Fig 3a) 
Accumulation of uncharged tRNAs, resulting from amino acid restriction or aaRS-inhibition, is sensed at 
the ribosome. The kinase GCN2, bound to the ribosome, binds uncharged tRNA, resulting in 
autophosphorylation and phosphorylation of the alpha subunit of the eukaryotic initiation factor 2 (eIF2α) 
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(GCN3 of the yeast mutant analyses) (41). GCN2 is considered a tRNA sensor since it binds tRNA 
through its histidyl-tRNA synthetase domain, and has been shown to bind uncharged tRNA with a 5-fold 
preference over charged tRNA in vitro (41, 42).  eIF2 is central to translation and mediates binding of 
initiator methionyl-tRNA to ribosomes, but phosphorylation of its alpha subunit inhibits recycling of the 
eIF2-MetTRNA-GTP ternary complex inhibiting cap-dependent protein translation (43).  Paradoxically, 
phosphorylation of eIF2α results in increased translation of specific mRNAs that contain upstream open 
reading frames in their 5’ leader including the bZIP transcription factor, GCN4 in yeast, or its functional 
equivalent in vertebrates, ATF4 (activating transcription factor 4), which sets in motion cascades of gene 
expression involved in amino acid metabolism and transport, redox homeostasis, and signaling (44-48).  
  
The AAR pathway is one of four ISR arms in mammalian cells (Fig 3b) 
In mammals the GCN2-eIF2α-ATF4 pathway has evolved to respond to a larger range of stressors with 
additional eIF2α kinases that each respond to distinct signals, and is referred to as the integrated stress 
response (ISR) (49). The ISR has primarily been studied in mammals and the extent to which the ISR is 
conserved across metazoa remains unclear.  Induction of the ISR by different stressors results in shared 
effects because all eIF2α kinases converge on eIF2α, but each activator kinase arm also has independent 
transcriptional readouts and functions (50-52). The AAR pathway is the sole ISR arm thought to signal 
through eIF2α alone. Our data now suggest that the accumulation of uncharged tRNA, like other ISR 
stress inputs, has signal readouts other than eIF2α. 
 
HF links nutritional stress response to tissue protection 
Our lab recently discovered the cellular target of halofuginone (HF), a semi-synthetic derivative of the 
natural product febrifugine, by showing that it binds EPRS, inhibiting its PRS activity (25). PRS is the 
cellular enzyme responsible for charging proline into its cognate tRNA.  Inhibitors of PRS or any aaRS 
act as amino acid restriction mimetics, activating the mammalian AAR pathway (19, 53). The plant 
alkaloid febrifugine, found in the roots of blue evergreen hydrangea, Dichroa febrifuga Lour, is the active 
ingredient of an ancient Chinese herbal remedy that has been used for roughly 2000 years for its 
therapeutic effects against several ailments including malaria and fever (54).  Its traditional use for 
malaria led to investigations to evaluate if it could be used to develop a new antimalarial drug.  The 
attempt failed due to potent side effects, but a search for a less toxic form in the late 1960s led to the 
design of the racemic halogenated derivative HF (55). Even prior to an understanding of its tissue 
mechanism, HF progressed to phase II clinical trials for fibrotic disease, bladder cancer, and Duchenne 
muscular dystrophy (25, 56-59).  Discovery of the HF target now links a variety of therapeutic effects, 
including anti-fibrotic, anti-inflammatory, anti-angiogenic, and anti-metastatic activities to tissue 
induction of nutrient stress response pathways (26, 58-61).  
 
V.  A novel nutritional stress response pathway    
 
The AAR pathway in eukaryotic cells shares hallmarks of the stringent response, in which uncharged 
tRNA signals amino acid depletion at the ribosome resulting in translational inhibition and adaptive and 
protective gene expression.  Our lab’s data point to the existence of an additional pathway in mammalian 
cells, in which the production of uncharged tRNA triggers a broad transcriptional cellular reprogramming 
to dampen inflammation and protect host tissues. GCN2, the signature mediator of the AAR pathway, is 
the only protein known to sense and signal in response to uncharged tRNA in mammalian cells. Studies 
from our lab using the aaRS-inhibitors HF and borrelidin to induce a tissue protective program in FLS; 
however, clearly show that this pathway is intact in cells lacking GCN2 (Kim et al, manuscript in 
preparation). The evolutionary conservation of the AAR pathway provides hints for where to start looking 
to uncover this unidentified pathway.  To identify candidate mediators of the novel tissue protective 
pathway, I looked to the evolutionary conservation of the AAR pathway.  GCN1 is a protein conserved 
throughout eukaryotes, whose function has only been studied in yeast.  In yeast, GCN1 forms a complex 
with GCN2, and is genetically required for GCN2 activation by uncharged tRNA (Fig 3c) (62-66).  A 
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large scaffold-like protein with no known enzymatic function, it is plausible GCN1 co-detects uncharged 
tRNA alongside GCN2, mediating the uncharged tRNA signal not only to GCN2 but to GCN2-
independent pathways.  In Chapter 3, I will study GCN1 as candidate mediator of the HF-driven GCN2-
independent effects observed by our lab, and test the possibility that GCN1 is a branch point in the 
mammalian AAR pathway. GCN1 provides a candidate mediator of the GCN2 independent effects of 
uncharged tRNA observed by our lab, representing a possible branch point within the AAR, which will be 
elucidated in my thesis.  For my doctoral thesis I will address the following questions: 
 
1.  Is the mammalian ISR conserved in the basal metazoan, Nematostella vectensis? 
2.  Is GCN1 a branch point in the mammalian AAR pathway?  
3.  What is the scope of the transcriptional program regulated by the novel HF-activated pathway, 
and what effectors mediate these GCN1-dependent GCN2-independent signals?  
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Fig 1 | Structure of Halofuginone 
 
 
 
 
 
 
 
 
Fig 2 | Cartoon of the bacterial stringent response. 
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Fig 3 | The Amino Acid Response (AAR) pathway and the Integrated Stress Response (ISR).  (a)  Cartoon of 
the AAR pathway.  (b)  Cartoon of the ISR.  (c)  Cartoon of the GCN2 pathway in yeast.  In yeast the GCN1-
GCN20 complex functions upstream of GCN2 and is required for GCN2 activation by uncharged tRNA. 
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CHAPTER TWO  
 
Characterization of Integrated Stress Response (ISR) Pathway and its Activation in the Basal 
Metazoan Lineage, Nematostella vectensis   
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INTRODUCTION   
 
The Integrated Stress Response (ISR) and the phylogenetic position of Nematostella 
 
Control of protein translation is a central component of adaptation to environmental stress. Understanding 
the mechanisms that underlie cellular adaptation to stress is necessary for the ability to monitor 
environmental health, predict novel hazardous chemicals, and predict how organisms will respond to 
toxicants and changing environmental conditions. Translational changes in response to stimuli modify the 
cellular proteome more rapidly than do transcriptional changes, and provide a first line of defense for the 
cell (1-3).  In addition, these translational changes regulate many of the subsequent transcriptional 
changes that control longer-term adaptations to stress (4-7).  In the cell, translation is primarily regulated 
at the point of translation initiation, and one of the primary proteins regulating translation initiation is the 
eukaryotic initiation factor 2 (eIF2) (8).  eIF2 is the central component of the integrated stress response 
(ISR), a signaling pathway that receives and integrates inputs from a range of stressors to mediate 
protective cellular effects via phosphorylation of eIF2.  
 
Cellular adaptation to stress in response to eIF2 phosphorylation is conserved from unicellular eukaryotes 
to mammals, but there is a wide range of variation in upstream pathway activators, downstream mediators 
and transcriptional responses between yeast and mammals (9, 10). The ISR’s broad conservation within 
eukaryotes suggests that it likely plays a similar role in animals from early diverging lineages such as 
cnidarians (11, 12).  Although it is clear that cnidarians respond to environmental stressors, little is known 
about the molecular signaling pathways that evoke these responses (13, 14). Signaling pathways 
regulating cellular stress responses have been extensively studied in classic model eukaryotes such as 
yeast, mice, and humans, but few studies have explored these pathways in early diverging animal 
lineages. Nematostella vectensis has become an increasingly popular cnidarian model in which to study 
questions about metazoan evolution and evolutionary development, in part due to its key phylogenetic 
position (15).  Cnidarians are an early branching metazoan lineage and in phylogenetic terms are the sister 
group to Bilateria (16).  The split between Bilateria and Cnidaria is estimated to have occurred about 600 
million years ago (17).  Nematostella belongs to class Anthozoa, which includes sea anemones and reef-
building corals. The genome of Nematostella has been sequenced and shows a slow rate of sequence 
evolution evidenced by a high level of conservation of ancestral genetic traits (18, 19). Nematostella 
therefor represents a good model to capture ancient functions of conserved genes and signaling pathways 
within metazoa (20).  Phylogenetic position, ease of laboratory culture, and its ecologically important and 
accessible habitat make Nematostella an interesting model for understanding the regulation of stress 
response in a cnidarian. 
 
The ISR is a broadly conserved regulatory event activated in response to diverse stressors, and exploring 
the consequences of this event has provided insight into the ways in which stress is sensed and responded 
to in classical eukaryotic models (21).  In this chapter, I identify key components of the ISR in 
Nematostella, which constitutes the first report of this functional stress response pathway in a non-
bilaterian metazoan. Nematostella is now the most evolutionarily distant animal from humans that has 
been shown to have a conserved ISR. Studying stress-triggered ISR pathway activation in Nematostella 
will help to understand the response and adaptation of this organism and related organisms to relevant 
marine stressors. Because of its key phylogenetic position, characterization of the ISR components in 
Nematostella could yield valuable insights into the roots and emergence of the more complex mammalian 
ISR. 
 
Evolutionary conservation and divergence of the ISR 
 
In the cell, translation is primarily regulated at the point of translation initiation. eIF2 is a key regulator of 
translation initiation and the central component of the ISR (22-25). A ternary complex that consists of 
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eIF2, GTP, and methionyl-tRNA recognizes methionine start codons. Phosphorylation of the α subunit of 
eIF2 (eIF2α) inhibits the recycling of the ternary complex, and it is this phosphorylation of eIF2α (at 
Ser51) by ISR kinases that makes eIF2 the central mediator of translational regulation by the ISR.  This 
translational control-based signaling cassette is conserved across eukaryotes and plays a central role in 
cellular adaptation to stress.  
 
The predominant effect of ISR pathway activation is a general reduction in the initiation of translation, 
which thereby reduces cell energy use and unfolded, or damaged, protein load.  Paradoxically, ISR 
pathway activation also up regulates synthesis of a small subset of proteins that are required for 
adaptation to stress, but that aren’t translated efficiently in an unstressed cell. Proteins that contain open 
reading frames upstream of the canonical start site (uORFs) in the 5’ untranslated regions (5’UTRs) of 
their mRNAs can respond to ISR pathway-driven upregulation (26). In the absence of cellular stress, 
translation initiation at these upstream starts suppresses translation at the canonical start codon, and 
inhibits synthesis of these stress mediators. Inhibition of ternary complex recycling by increased eIF2α 
phosphorylation leads to increased read-through of the upstream starts, allowing increased translation 
initiation at the canonical start site (27, 28).  In yeast, the transcription factor GCN4 is the key mediator of 
ISR pathway-driven transcriptional changes (29).  In vertebrates, its functional equivalent is ATF4. Each 
of these stress-mediating mRNAs contains multiple uORFs that confer dramatic upregulation of these 
transcription factors in response to eIF2α phosphorylation (30). Other uORF-containing transcripts that 
are translationally upregulated during ISR pathway activation include CHOP and CYP2B (31).  Although 
uORFs are necessary for the translational upregulation component of stress-driven ISR pathway response, 
they do not appear to be sufficient to confer this response. Additional parameters important for uORF 
regulation (uORF number, frame, or position relative to canonical start) are poorly understood (26, 32, 
33). 
 
Cellular stress activates the ISR via one or more eIF2α kinase that then phosphorylate eIF2α (Fig 1).  
Mammals have a set of four eIF2α kinases with similar kinase domains, but distinct regulatory domains 
that facilitate activation by specific inputs allowing each kinase to primarily respond to a distinct type of 
cellular stress (9, 34). These kinases include GCN2 (general control non-derepressible-2), PERK (PKR-
like ER kinase), HRI (heme-regulated inhibitor), and PKR (protein kinase double-stranded RNA-
dependent) (9).  
 
The number of eIF2α kinases and the range of cellular inputs activating the ISR expanded from yeast to 
mammals with one kinase represented in S. cerevisiae and four in mammals (Fig 2) (9, 24).  GCN2 is 
represented throughout eukaryotes and is activated by uncharged transfer RNAs (tRNA).  In yeast GCN2 
responds to amino acid, glucose, or purine starvation, and high salinity (35).  In mammals, GCN2 
responds to amino acid and glucose starvation, but also UV irradiation and proteasome inhibition (10).  
PERK is an endoplasmic reticulum (ER) trans-membrane protein that has only been found in metazoans, 
which is activated by unfolded proteins in the ER, referred to as ER stress (36).  The extent of 
conservation of HRI across eukaryotes is not known and its absence in traditional invertebrate models has 
led to the misinterpretation of HRI as a vertebrate specific eIF2α kinase (37, 38).  It has been found in 
mammals, some species of arthropods, and putatively in one species of fungi, but not S. cerevisiae (37-
39).  HRI senses low heme levels and also responds to heat shock and heavy metals (40, 41).  Lastly, 
PKR has only been identified in vertebrates, where it senses double-stranded RNA responding to viral 
infection (9).  ISR-mediated translation inhibition allows the cell to preserve energy and amino acids 
during amino acid deprivation, reduce the ER protein load to allow the ER to fold or dispose of misfolded 
proteins during ER stress, and couple the synthesis of globin to cellular heme levels particularly when 
heme levels are low (10, 37, 42).  In addition, ISR induction increases transcription of a subset of genes 
that aid the cell in its recovery.  Conservation of GCN2 across existing eukaryotes indicates that a GCN2-
like kinase was present in the first eukaryotes that later diversified, but the evolution of these kinases is 
not well understood (11, 12). 
25 
 
The conservation of mammalian ISR gene targets has not been investigated in non-vertebrate metazoans.  
As a consequence of the shared phosphorylation of eIF2α by multiple kinases in mammals, common 
ATF4 responsive genes are transcribed in response to diverse stresses such as amino acid limitation and 
ER stress (21, 43).  ATF4 targets include genes important in cell recovery from stress or ultimately 
apoptosis if the stress is unresolved.  Characteristic mammalian ATF4 targets include genes involved in: 
amino acid metabolism and transport including ASNS (asparagine synthetase) (44-46), SNAT2 (sodium-
coupled neutral amino acid transporter 2) (47, 48), and xCT (cysteine/glutamate transporter) (49, 50); 
proteostasis and oxidative balance including HERP1 (homocysteine-inducible, ER stress-inducible, 
ubiquitin-like domain member 1) (51-54) and CHAC1 (glutathione-specific gamma-
glutamylcyclotransferase 1)  (55); and negative feedback regulation of the ISR including GADD34 
(growth arrest and DNA damage-inducible protein ) (56), CHOP (CCAAT-enhancer-binding protein 
homologous protein), and TRB3 (tribbles homolog 3) (57-59).  In S. cerevisiae, GCN4 elicits 
transcriptional activation of at least 539 genes, primarily amino acid biosynthetic genes (35).  Notably, 
ASNS is the best-characterized mammalian ISR induced target; however, yeast ASNS homologues are 
not ISR induced (35, 45, 60, 61).  Characterization of the conservation of these targets in Nematosella 
could yield insight into the function and limits of ISR-induced changes to stress adaptation.       
 
Using ISR pathway activation to monitor marine environmental and organismal health 
 
Marine environments are increasingly impacted by anthropogenic activities.  Over 50% of the human 
population lives in coastal areas in the United States and coastal waters are especially impacted by human 
activity (62). The estuarine habitat of Nematostella constitutes a particularly ecologically and 
economically important ecosystem making accurate monitoring of habitat health important (62).  
Compounding the natural variability of these ecosystems, estuarine environments are highly impacted by 
human activities resulting in the introduction of toxic chemicals and alterations in fresh and saltwater 
inputs (63). Climate change is likewise predicted to cause increasing temperatures (64).  Nematostella as 
an infaunal and largely sedentary animal is particularly exposed to accumulation of toxic chemicals in 
sediments and physical changes in its immediate environment, suggesting the use of Nematostella as a 
sentinel organism. In addition, estuaries exhibit natural variability in major environmental parameters 
including temperature, salinity, ultraviolet radiation, oxygen, and reactive oxygen species (65, 66) and as 
a result, estuarine species such as Nematostella, exhibit broader physiological tolerances than freshwater, 
marine, or terrestrial species (63). The biochemical basis for this broad tolerance in Nematostella is not 
fully understood.  Elevated temperatures, changes in salinity, and heavy metals are only a subset of the 
stressors that can activate the ISR in eukaryotic cells that are known environmental stressors affecting 
marine organisms.  
 
Environmental stressors are diverse, but often cause similar damage or alterations to the cell.  Elevated 
temperature and hypertonic stress primarily induce protein misfolding in the cytoplasm, while heavy 
metal exposure induces protein misfolding in the ER.  These stressors trigger ISR pathway activation in 
mammalian cells (67-71).  Protein misfolding and subsequent ISR induction has been most studied in the 
ER.  The reducing agent, dithiothreitol (DTT) is a well-established ER stress inducer that disrupts 
disulfide bonds resulting in misfolded ER proteins.  In the experiments described below, I utilize DTT to 
mimic a range of environmental stressors.  Treatment of Nematostella with DTT produces cellular ER 
stress and subsequent activation of the ISR pathway in this organism. This observation is the first 
demonstration of induction of the ISR in an animal from a basal lineage, as well as the first demonstration 
of an intact ER stress response in Nematostella.  
 
Analysis of the Nematostella genome predicts conservation of the core mammalian ISR.  Likewise, 
comparison of eIF2α orthologues predicts a high degree of epitope conservation, which, in fact, has 
proved sufficient to allow the use of commercial mammalian antibodies for the detection of both 
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eIF2α and peIF2α proteins in these studies. By exposing Nematostella to a range of chemical and 
physical triggers, then assessing the phosphorylation state of eIF2α and putative ISR transcriptional 
mediators, I have identified and begun to characterize multiple arms of the ISR in this organism. In these 
experiments, I use chemicals, (DTT and halofuginone (HF)), which mimic diverse environmental stress 
(oxidative stress and dietary restriction, respectively). I further show that exposure to conditions that 
mimic physical environmental stressors and pollution in estuaries, such as elevated temperature, increased 
salinity, and copper results in increased eIF2a phosphorylation or ISR target gene transcription, thereby 
coupling ISR pathway activation to environmental stress in Nematostella. 
 
RESULTS 
 
The Nematostella genome contains major components of the mammalian ISR  
 
To determine whether the major components of the ISR are present in the basal metazoan, Nematostella, I 
searched the Nematostella genome for the presence of orthologues to the mammalian kinases, the central 
transcription factor, ATF4, and downstream ISR transcriptional target genes.  Human protein query 
sequences were blasted against the Joint Genome Institute (JGI) assembly of the Nematostella genome 
and were considered orthologues if reciprocal blasts against the human genome yielded positive matches.  
The nucleotide sequences of positive JGI hits were further blasted against the Nematostella transcriptome 
published by Tulin et al. 2013 to determine whether the JGI sequence represented the full transcript (72). 
Three of the four mammalian eIF2α kinases, GCN2, PERK, and HRI have orthologues in the 
Nematostella genome (Fig 3, Fig S1). Phylogenetic analysis of eIF2α kinases from 13 eukaryotic 
genomes including Nematostella, yeast, and 11 additional metazoan species shows that the Nematostella 
kinases fall within expected kinase member clades, supporting these Nematostella kinases as true 
orthologues of mammalian GCN2, PERK, and HRI (Fig S1).  Specific residues have been previously 
identified in mammalian eIF2α kinases that distinguish eIF2α kinases from other kinases (73).  These 
residues are present in all three Nematostella kinases (data not shown), establishing these kinases as 
eIF2α kinases.  eIF2α kinases contain similar kinase domains responsible for phosphorylating eIF2α but 
have distinct regulatory regions that respond to distinct cellular signals (Fig 3a).  Sequence identity 
between the kinase domains of each Nematostella eIF2α kinase with its respective human orthologue is 
greater than between any of the other human eIF2α kinase family members (Fig 3b).   
 
To determine whether the characteristic domains of each of the mammalian kinases are present in the 
Nematostella kinases, the Nematostella kinases were searched for conserved domains using NCBI 
Conserved Domain Search.  NvGCN2 contains the characteristic pseudo-kinase and histidinyl-tRNA 
domains found in yeast and mammalian GCN2 that are required for kinase activity and uncharged tRNA 
binding, respectively (74).  In addition NvGCN2 contains the characteristic RWD domain at its N-
terminal domain responsible for protein interaction (Fig 3a).  NvPERK contains a luminal domain that is 
responsible for dimerization and sensing of unfolded proteins (75).  A putative ER signal peptide or long 
stretch of hydrophobic residues is also present within the N-terminus (N-CFSSVVKFVAVMATFAN 
EFGNVSPN-C) (Fig 3a).  The kinase domain of NvHRI is most similar to HRI; however the N-terminal 
portion of NvHRI (responsible for heme binding and detection in mammalian HRI) shares low sequence 
identity (26.0%) with mammalian HRI (Fig 3a).  Only a subset of residues within this region may be 
required for heme binding.  Residues important for heme binding in mammals including His75, His119, 
His120, and Cys409 are not conserved and there are no Cys-Pro motifs, which in mammals participate in 
heme binding (76, 77).  Functional studies will be required to confirm if NvHRI responds to heme levels.  
Given the importance of heme and hemeproteins in cells (gas transport, chemical catalysis, and electron 
transfer) and the presence of HRI in a wide range of eukaryotic species it would not be surprising if 
NvHRI responds to heme levels. The presence of NvHRI confirms that HRI is not restricted to vertebrates 
but is likely represented throughout eukaryotes and has been lost in several lineages including S. 
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cerevisiae, C. elegans and D. melanogaster.  Conservation of NvPERK demonstrates that PERK appeared 
evolutionarily as early as Nematostella on the metazoan evolutionary tree.  PERK was already present in 
the cnidarian-bilaterian ancestor supporting PERK as a metazoan-specific kinase.  The lethal phenotype 
of PERK null mice and the appearance of endogenous ER stress with metazoan development and cellular 
differentiation suggest PERK may have been important in mediation of endogenous ER stress during 
evolution (75, 78). Within all three Nematostella eIF2α kinases, threonine residues responsible for kinase 
autophosphorylation in mammals are conserved.  This demonstrates that Nematostella contains 
orthologues to 3 of the four mammalian kinases.    
 
ATF4 and ISR transcriptional targets conserved in Nematostella 
The transcription factor, ATF4, is currently considered the primary mediator of early ISR-induced 
transcriptional changes (79).  An ATF4 bZIP domain was recently identified in the Nematostella genome; 
however, this study did not identify the full coding sequence and this gene is not included in the JGI 
predicted gene database (80).  This explains why a blast search of the Nematostella genome with the 
human protein sequence yields no predicted protein hits within JGI.  The nucleotide sequence of the 
NvATF4 bZIP domain is however present in the JGI genome and a full transcript encompassing this 
NvATF4 bZIP domain can be found in the Nematostella transcriptome published by Tulin et al. 2013 (72).  
This transcript designated NvATF4 shares only 22.9% identity with its human counterpart (Fig 1b), but 
shares 44.2% identity within the bZIP domain.  Phylogenetic analysis of bZIP domains from bZIP 
transcription factors across 13 eukaryotic species shows that NvATF4 groups with other metazoan ATF4 
orthologues supporting NvATF4 as an orthologue of mammalian ATF4 (Fig S2).  Blast searches of three 
other cnidarian species (the hydroid, H. vulgaris; the coral, A. digitifera; and the anemone, A. 
elegantissimma) with full-length NvATF4 yield orthologues in these additional cnidarians, which share 
20.3, 28.9, and 39.9% identity with Nematostella.  Comparison of the bZIP domains of these orthologues 
also share higher identity than comparison between the full-length sequences (49.6; 59; 69.2%) 
suggesting NvATF4 orthologues are found throughout cnidarians.  Additional reciprocal blast searches of 
two species from two of the earliest branching metazoan lineages: Trichoplax (T. adhaerens) and sponge 
(A. queenslandica), with full-length human ATF4 yields ATF4 orthologues in both these species 
supporting the presence of ATF4 across metazoans.   
 
A key characteristic of ATF4 and GCN4, that is essential for ISR translational regulation is the presence 
of uORFs in the 5’UTR of the transcript (27).  Analysis of the NvATF4 transcript shows the presence of 
four uORFs in the 5’ UTR that are out of frame with the main ORF.  A characteristic overlapping uORF 
of human ATF4 facilitates inhibition of ATF4 translation during non-stress conditions by allowing the 
ribosome to pass by the primary start site.  Both the presence of NvATF4 and uORFs within the NvATF4 
5’UTR suggests that transcriptional changes by the ISR are mediated similarly to mammals via 
upregulation of NvATF4 translation.  
 
In mammals, ATF4 expression induces transcription of characteristic genes including both effectors of 
stress adaptation and negative feedback regulators of the ISR.  To determine if these genes are present in 
Nematostella, human amino acid sequences were used in blast searches of the Nematostella genome and 
hits that yielded positive reciprocal blast matches either to the query itself or a closely related gene within 
the same protein family were considered orthologues or homologues, respectively.  In mammals, the ISR 
is negatively regulated by two PP1 targeting proteins or eIF2α phosphatases: GADD34 and CReP (56, 81). 
The first invertebrate eIF2α phosphatase was recently identified in D. melanogaster (82).  To identify a 
Nematostella eIF2α phosphatase homologue, the Nematostella genome was searched as described but 
with the D. melanogaster phosphatase as query because the human query yielded no results.  
Nematostella contains one eIF2α phosphatase designated NvEPP, which contains a PP1 binding KVxF 
motif in the C-terminal region like mammalian and fly GADD34. No other invertebrate eIF2α 
phosphatases have been identified.  
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In addition to ISR regulatory genes, ATF4 expression induces genes involved in amino acid biosynthesis 
and transport, ER homeostasis, and oxidative balance.  Mammalian ISR targets with identified 
Nematostella homologues are shown in Fig 3c.  Nematostella contains orthologues of ASNS, HERP1, 
CHAC1, TRB3 and putative homologues or related proteins of mammalian SNAT2 and xCT (Fig 3c).  
NvASNS and NvHERP share the highest sequence identity with their human orthologues.  ASNS is the 
best-studied ISR target, is highly conserved in Nematostella as expected, and shares 58% identity with 
human ASNS.  In addition, within 2000 base pairs of the ASNS translational start site are 5 putative 
ATF4 binding sites, supporting NvATF4 regulation of NvASNS.  Other Nematostella ISR target 
homologues also contain at least 2 putative ATF4 binding sites.  This is the most basal metazoan lineage 
in which conservation of ISR target genes have been examined, and suggests that many mammalian ISR 
targets are highly conserved in this basal metazoan.  
Phosphorylation of eIF2α and putative ISR target genes are induced by the reducing agent, DTT, as 
in mammalian cells 
 
To test whether the ISR is induced similarly to the ISR in mammals, adult Nematostella were exposed to 
dithiothreitol (DTT).  eIF2α phosphorylation (peIF2α) and induction of putative ISR target genes were 
assayed by immunoblot and qPCR.  DTT disrupts protein folding by disrupting disulfide bonds, causing 
ER stress and inducing the ISR.  Phosphorylation of eIF2α in Nematostella increased significantly 
following exposure to DTT for four hours (Fig 4a left).  RNA levels of ISR targets were also induced 
significantly (Fig 4a right).  ASNS showed the greatest fold increase.  This induction is much greater than 
ASNS induction by ISR inducers in mammalian cells. HERP and TRB showed the greatest induction 
among the remaining target genes.  The timecourse of peIF2a and ISR target gene transcription was 
similar to that of mammalian cells.  In mammalian cells peIF2α is induced within minutes and declines 
after 4 to 6 hours (45), while ASNS transcription subsequently increases and starts to decline after 4-6 
hours (4).  This delay of transcriptional induction compared to peIF2α is consistent with regulation of 
ASNS by peIF2α.  In Nematostella peIF2α also occurred within 15 minutes of DTT exposure (Fig 4b left) 
while no ASNS transcription was observed after a 15 minute DTT exposure (data not shown).  
Transcription of ASNS and HERP increased within 2 hours of DTT exposure (Fig 4b right) and 2 hours 
after a 15-minute exposure to DTT (data not shown).  Both phosphorylation and ASNS levels were 
significantly induced by 1 and 4 mM DTT (Fig 4c), which is within the range used to induce the ISR in 
mammalian cells (83). DTT induction of ASNS and HERP was also seen in juveniles (data not shown).  
The strong, rapid induction of both conserved ISR transcriptional responses and of eif2a phosphorylation 
by an ER stressor in Nematostella provides direct functional evidence that the ER stress component of the 
ISR is conserved in Nematostella, and responds to an ER stressor over a dose range and time course 
similar to that seen in mammalian cells. 
 
To directly test whether PERK mediates eIF2α phosphorylation by DTT in Nematostella, adults were 
exposed to the mammalian PERK inhibitor, GSK2606414, followed by exposure to DTT, and peIF2α 
levels assayed.  Decreased eIF2α phosphorylation in 293T cells with PERK inhibitor followed by DTT 
exposure confirmed inhibition of mammalian PERK (Fig 5a).  In Nematostella only the highest dose (100 
uM) of inhibitor decreased phosphorylation (Fig 5b).  While this could be due to inhibition of NvPERK, 
the high dose (1000x the mammalian dose) required makes it difficult to conclude that the inhibitor 
effects are specific to this kinase. Whether the low efficacy of GSK2606414 in Nematostella is due to 
poor uptake or penetrance, divergence between the NvPERK and mammalian PERK kinase domains, or 
other factors, is not clear.  
 
In vertebrates and D. melanogaster peIF2α is enriched in tissues that secrete large amounts of proteins, 
and therefore have an elevated protein-folding load in the ER (78).   To examine localization of peIF2α in 
Nematostella, immunohistochemistry was performed with peIF2α antibody in juveniles treated with or 
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without DTT (Fig S3).  DTT-stress stimulated peIF2α staining is detectable and is localized towards the 
oral end of the animal (Fig S3b, h).  Localization of peIF2α in unstressed animals was not clear, 
suggesting that there is little endogenous peIF2α in these specimens or it is significantly weaker than that 
of DTT exposed animals and was not detected here (Fig S3a).  Localization of peIF2α in juvenile 
Nematostella shows no obvious pattern at the level of resolution provided by the experimental setup. 
Comparison of peIF2α-specific FITC and nuclear DAPI staining does suggest that NvpeIF2α is localized 
to the cytoplasm, as expected.  Sectioned animals and confocal microscopy, along with additional 
antibody staining to identify specific cell types will be necessary to determine whether peIF2α is enriched 
in certain parts or cells of this animal.  A Nematostella specific antibody could be raised; however, due to 
the high conservation of the serine phosphorylation site and surrounding sequence it is unlikely that the 
Nematostella specific antibody would be advantageous.  These results replicate the previous results of 
increased peIF2α phosphorylation after exposure to the ER stress inducer, DTT. 
 
Halofuginone, a chemical inducer of the GCN2 arm of the mammalian ISR, induces the ISR in 
juvenile Nematostella  
 
The GCN2 arm of the ISR is often referred to as the amino acid response (AAR).  Halofuginone (HF) is 
an AAR pathway activator that specifically binds and inhibits the enzyme, prolyl tRNA synthetase 
(EPRS) leading to the production of unbound tRNAs and the phosphorylation of GCN2 (84).  EPRS is 
conserved in Nematostella suggesting activation of NvGCN2 by HF is likely (85).  To determine whether 
HF activates the ISR in Nematostella, adults and juveniles were exposed to HF, and assayed for eIF2α 
phosphorylation and induction of the transcriptional readouts most highly induced following DTT 
exposure: ASNS and HERP.  HF significantly increased eiF2α phosphorylation and induction of ASNS in 
juvenile Nematostella (Fig 6); however, neither eIF2α phosphorylation nor ASNS and HERP 
transcription were induced in adults (data not shown).  This could indicate a difference in the physiology 
of juveniles compared to adults or HF is simply able to permeate the smaller juveniles more efficiently.  
The significant induction of peIF2a and ASNS support the use of HF to activate the AAR via GCN2 in 
Nematostella, and possibly as a method to mimic amino acid starvation.  
 
Exposure to the environmental stressors: temperature, salinity, and copper activates the ISR in 
Nematostella 
 
To evaluate the relevance of the ISR to environmental stressors that threaten marine and human health, 
induction of peIF2α and the transcriptional targets: NvASNS and NvHERP, shown to increase after 
exposure to two mammalian ISR inducers were assayed subsequent to exposure to low and high 
temperatures, low and high salinities, and copper. In yeast and mammals, heat shock results in eIF2α 
phosphorylation (38, 39).  Temperatures collected in a pool in Sippewissett Marsh, MA showed that 
temperatures varied between 1.3 and 43.7°C and therefore Nematostella must tolerate wide variations in 
temperature (14).  In Nematostella phosphorylation of eIF2α increased significantly following a 30 
minute exposure to 37°C (Fig 7a).  Longer exposure of adult Nematostella to 37°C (1 hour or more) was 
lethal to the animals, and the lack of peIF2α induction at these times may reflect cell death.  It is possible 
that as infaunal organisms, animals in the field do not actually experience such high temperatures.  In 
addition, animals in the field likely do not experience such abrupt changes in temperature, perhaps 
allowing adaptation to subsequent higher temperatures not replicated in these experiments.  As observed 
for DTT, eIF2α phosphorylation was induced by heat shock within 10 minutes of exposure (Fig 7b).  
Exposure to 4°C did not induce eIF2α phosphorylation (Fig 7c). NvASNS transcription was stimulated 
3.5 hours after a 30 minute exposure to 37°C (Fig 7d).  In addition, transcription of the ER chaperone, 
BiP (grp78), a member of the Hsp70 family and a major effector of ER stress adaptation, was induced by 
brief heat stress (Fig 7d).   
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Because Nematostella inhabit pools that undergo large changes in salinity, these animals must adapt to 
both hypertonic and hypotonic stresses.  The AAR can mediate adaptation to hypertonic stress in both C. 
elegans and yeast (67, 86, 87), and therefore I examined the effects of salinity changes on Nematostella.  
Nematostella have been documented to survive salinities ranging from 2 – 54 parts per thousand (ppt) and 
are raised in the lab at 15 ppt (88).  Exposure to 0 or 50 ppt artificial seawater for four hours significantly 
induced NvASNS expression at 50 ppt but not 0 ppt (Fig 7e) consistent with the possibility that 
hypertonic stress induces the ISR possibly via NvGCN2 in Nematostella.  Further experiments will be 
required to determine that peIF2α is induced and whether NvASNS induction by increased salinity is due 
specifically to NvGCN2 and ISR activation.  
 
Copper is a common marine pollutant, and copper and other metals have been shown to induce the ISR.  
For that reason I examined the effects of copper exposure on NvASNS and NvHERP expression (40, 70, 
89).  Trace metals are particularly prevalent in estuaries, and accumulate to levels orders of magnitude 
higher in coastal waters than in the open ocean (90).  Metal ions can directly interact with cellular 
proteins, indirectly interact through metal-induced oxidative damage of proteins, and can affect the 
function of metal requiring proteins and enzymes leading to oxidative stress (90).  Copper is a commonly 
used test example for metal toxicity and has been shown to induce ER stress (91-94).  Metal toxicity is 
generally tested using sublethal concentrations, and in vertebrate cells copper concentrations ranging from 
1-50 µM are typically used (89, 92, 93).  Nematostella exposed to 20 µM copper significantly induced 
NvASNS expression but not NvHERP (Fig 7f), consistent with ISR induction, but additional experiments 
will be required to determine whether copper induces NvpeIF2α and the specificity of induction to the 
ISR.  These results are consistent with activation of the ISR by heat stress, hypertonic stress, and copper 
exposure indicating a role for the ISR in environmental stress response in Nematostella.   
 
DISCUSSION 
 
These results establish that the major components of the mammalian ISR are present in Nematostella 
vectensis and provide evidence for ISR pathway activation by chemicals and environmental stresses. The 
expansion of inducers, effectors, and functions of the ISR seen in mammals compared to those present in 
yeast were most likely present in the last common ancestor between cnidarians and bilaterians.  The 
conservation of NvPERK confirms that PERK was present in the cnidarian-bilaterian ancestor, backing 
PERK as a metazoan-specific kinase. In addition, the presence of NvHRI confirms that HRI is not 
restricted to vertebrates but is likely represented throughout eukaryotes and has been lost in several 
lineages.  The Nematostella genome contains an ATF4 orthologue with uORFs suggesting similar 
function to mammalian ATF4 and that the central function of ATF4 in the transcriptional response of the 
ISR is conserved as far back as cnidaria.  Finally several targets of the mammalian transcriptional 
response are conserved and are induced by chemical and environmental stresses known to induce the ISR 
in other species.  ASNS in particular is highly induced by both the chemical and environmental stresses 
used.  In particular, DTT results in dramatic induction of ASNS and strong induction of peIF2a.  ER 
stress can be caused by a variety of environmental stressors underscoring the likely central role of the ISR 
in stress response in Nematostella and other marine organisms.  The high conservation of the central core 
of this pathway in basal metazoa demonstrated by this chapter suggest the application of these tools for 
the study of the ISR and stress response in other non-model marine metazoans. 
 
The ecology of Nematostella and the conservation of many components of the mammalian ISR 
underscore the promise of Nematostella as an indicator species of environmental health.  Transgenic 
mice, flies, and zebrafish carrying ISR reporters have been successful in indicating physiological stress 
due to endogenous and external sources (89, 95, 96).  A recent study took advantage of a transgenic 
zebrafish line harboring a human upstream open reading frame of an ISR translational target gene fused 
with GFP.  The reporter reliably reflected physiological stress induced by exposure to heavy metals and 
endocrine disrupting chemicals.  Intriguingly, different tissue-specific GFP expression patterns were 
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observed in response to different chemical stressors.  Animals exposed to field-collected water samples 
were able to correctly detect various pollutants (89).  The advantage of this sort of transgenic model is 
that it reflects the physiological stress of the organism without respect to a specific stressor allowing 
detection of unexpected hazardous chemicals, stresses, and the real-life reality of multiple stress exposure, 
while traditional chemical analysis and transcriptional targets of known stressors can provide specificity.  
The ideal ecology of Nematostella as an estuarine, sedentary, yet stress-resistant animal could provide a 
perfect system as a similar transgenic model for estuarine health. The work described here, which 
identifies and characterizes intact and functional ER stress and AAR pathway arms of the ISR in 
Nematostella, lays the groundwork for the development of Nematostella into a sentinel organism for an 
essential and highly threatened marine ecosystem. 
 
Proteostasis, or the maintenance of the proper function of cellular proteins, is disrupted by multiple 
stressors and causes ER stress and therefor likely activates PERK.  Recent studies in C. elegans; however, 
implicate GCN2, and thus the AAR pathway arm of the ISR, in proteostasis (67, 86).  Since maintenance 
of proteostasis is central to adaptation and the potential toxicity of environmental stressors, understanding 
the regulation of proteostasis should be central to understanding environmental stress toxicity and the 
capacity for organismal stress adaptation.  Although reduction in protein synthesis is widely observed in 
response to environmental stress, the relationship between reductions in protein synthesis and improved 
stress resistance is not understood (86).  Inhibition of translation initiation in C. elegans during hypertonic 
stress occurs via activation of GCN2, and translation inhibition is required to reduce protein damage 
during hypertonic stress (67, 86).  Induction of ASNS by hypertonic stress in Nematostella suggests that 
the ISR may play a similar protective role during hypertonic exposure.  Whether the Nematostella 
hypertonic response occurs through GCN2, as in C. elegans and the role of this response in proteostasis 
will be interesting areas for further investigation. 
 
GCN2 and the AAR are responsible for adaptation to nutrient limitation and contribute to the beneficial 
effects of lifespan extension and prevention of age-related diseases observed in model metazoan species 
in response to caloric restriction (84).  Nematostella are able to survive extended periods of time without 
food, during which they shrink, but quickly regain size upon feeding.  Phosphorylation of eIF2α is 
elevated in highly stress resistant states of other animals such as hibernating mammals, implicating ISR 
involvement in these survival states (97).  AAR pathway activation following amino acid deprivation in 
mammals is known to induce autophagy, suggesting the ISR may play a significant role in mediating 
survival during hibernation and extended states of caloric restriction (23).  The work presented here 
provides a basis for future studies of these phenomena.   
 
Through the exposure of Nematostella to a range of chemical and physical triggers, I’ve demonstrated the 
conservation of and characterized the activation of multiple arms of the ISR pathway in this organism. 
The work presented here demonstrates the conservation of the mammalian core of the ISR in a basal 
metazoan and validates assays that can be used to follow known components of ISR activation in a range 
of non-model metazoans, where experimental tools for functional protein studies are limiting. Further 
work in this thesis will explore new pathways, distinct from the core ISR, that mediate responses to amino 
acid limitation, and examine whether these additional stress responses are also shared across metazoans. 
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METHODS 
 
Identification of ISR genes in Nematostella  
ISR target genes were identified in the Nematostella genome through BLASTp searches of the Joint 
Genome Institute (JGI) Nematostella vectensis assembly using the human amino acid ISR gene sequences 
whose accession numbers are given in Table S1.  The JGI nucleotide sequences were blasted against the 
Nematostella developmental transcriptome published by Tulin et al. 2013 using BLASTn to assess 
whether the JGI sequence was complete (72).  In cases where multiple sequences matched, sequences 
were assembled in silico to produce the most complete sequence.  The identifiers of the sequences used in 
this study are given in Table S1.  
 
Phylogenetic Analyses of eIF2α Kinases and bZIP Transcription Factors  
To determine evolutionary relationships of NveIF2α kinases with other metazoan eIFα kinases, eIF2α 
kinase homologues from additional species were obtained by using amino acid sequences of the four 
human eIF2α kinases (accession numbers supplied in Table S1) to search Saccharomyces cerevisiae, 
Amphimedon queenslandica, Acropora digitifera, Nematostella vectensis, Hydra vulgaris, 
Caenorhabditis elegans, Drosophila melanogaster, Ciona intestinalis, Strongylocentrotus purpuratus, 
Branchiostoma floridae, Petromyzon marinus, Danio rerio, and Homo sapiens genomes using BLASTp.  
S. cerevisiae, C. elegans, C. intestinalis, D. melanogaster, D. rerio, and P. marinus genomes were 
searched through ENSEMBL, the A. digitifera genome was searched through the OIST Marine Genomics 
Genome Browser, the A. queenslandica genome was searched through ENSEMBL METAZOA, and 
Branchiostoma floridae, Strongylocentrotus purpuratus, and Hydra magnipapillata were searched 
through NCBI (98, 99).  Sequences used for subsequent analysis were those with the highest scores, 
lowest e-values, and that yielded reciprocal best BLAST hits.  Protein accession numbers of protein 
sequences are given in Table S1.  Sequences were aligned with Muscle 3.6 and manually edited in 
Geneious 5.6.6 (100, 101).  ProtTest was used to determine the best model of protein evolution (102). 
Maximum likelihood analysis was run using RAxML v.8.0.0 (103) with the following model and 
parameters: LG+I+G+F. One thousand rapid bootstraps were performed.  Figtree v.1.4.0 was used for tree 
visualization (104). 
 
To determine the evolutionary relationships of Nv bZIP transcription factors with other eukaryotic bZIP 
transcription factors, bZIP transcription factors from Saccharomyces cerevisiae, Monosiga brevicolis, 
Nematostella vectensis, Caenorhabditis elegans, Drosophila melanogaster, Ciona intestinalis, and Homo 
sapiens from Amoutzias et al. 2007, Fassler et al. 2002, Reinke et al. 2013, Vinson et al. 2002, and 
Yamada et al. 2003 were used to construct a maximum likelihood tree.  bZIP domain sequences for all 
taxa were aligned with Muscle 3.6 and manually edited in Geneious 5.6.6 (100, 101).  The subsequent 
maximum likelihood analysis was performed as described above for the eIF2α kinases with the following 
model and parameters: LG+G.  
Nematostella Culture 
Nematostella vectensis were cultured under standard conditions (0.45 µm filtered seawater (for 
experiments conducted at WHOI) or artificial seawater (Instant Ocean) (for experiments conducted at 
HSDM) diluted to 13 ppt, four weekly brine shrimp feedings, and weekly water changes) similar to 
previously described conditions (105).  Spawning was performed according to (106) with additional 
mussel ovary feeding the day prior to spawning.   
 
Mammalian Cell Culture 
293T (ATCC) were cultured at 5% CO2 at 37°C in DMEM supplemented with 10% fetal bovine serum, 
L-glutamine, non-essential amino acids (NEAA), and antibiotics.  
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Nematostella Chemical and Environmental Stress Exposures 
Adult Nematostella starved for three to four days were transferred to 24-well tissue culture plates with 13 
ppt seawater.  One animal was placed in each well.  After transfer, plated animals were incubated at room 
temperature overnight.  For chemical and salinity exposures, water was replaced with 1 mL per well of 13 
ppt seawater containing the appropriate concentration of chemical (DTT, HF (Whitman lab), PERK 
inhibitor (GSK2606414, Selleckchem), copper sulfate (Sigma), or sea salt (Instant Ocean)).  For 
temperature exposures individual animals were placed in 1.7 mL centrifuge tubes with 1 mL of 13 ppt 
seawater and placed on a heat block at the appropriate temperature.   
 
Protein Extraction, SDS PAGE, and Immunoblotting 
For protein extraction, animals were placed on ice and rinsed 2x with 13 ppt seawater.  For experiments 
performed at WHOI, animals were homogenized with a 1 mL dounce homogenizer (Wheaton) in 750 µL 
high salt RIPA buffer (400 mM NaCl, 1% NP-40, 0.5% DOC, 0.1% SDS, 50 mM Tris pH 7.5, 1 mM 
EDTA with protease and phosphatase inhibitors: 20 nM Calyculin A, 60 nM Okadaic Acid, 1 mM PMSF, 
1 mM NEM, and 1X Complete protease inhibitor cocktail (Roche)).  Samples were incubated for 30 
minutes at 4°C on a rotisserie tube rotator.  After centrifugation (4°C, 20 minutes, 16,000 G), the 
supernatant was collected and the protein content quantified with the Coomassie Plus (Bradford) protein 
assay kit (Thermo Scientific).  For experiments performed at HSDM, animals were homogenized in 500 
µL high salt RIPA at 4°C in Red Bullet Bead Lysis kit centrifuge tubes (Next Advance) for 15 minutes at 
level 8 in a bullet blender homogenizer (Next Advance).  After centrifugation (4°C, 20 minutes, 16,000 
G), the supernatant was collected and the protein content quantified with the Pierce BCA protein assay kit 
(Thermo Scientific).  For both methods one animal was homogenized per sample.   
 
Protein samples were diluted in 3X Laemmli buffer (160 mM Tris pH 6.8, 6% SDS, 20% glycerol, 0.01% 
bromophenol blue, 0.04% β-Mercaptoethanol), boiled for 5 minutes, and electrophoresed through pre-cast 
Bolt 4-12 % Bis-Tris Plus gels (Invitrogen).  The amount of total protein loaded per well was 
standardized across each experiment.  Proteins were transferred to nitrocellulose membrane (GE 
Healthcare), blocked with 5% milk and blotted with the following antibodies: eIF2α (pS51), eIF2α, β-
tubulin, actin (Sigma) (all from Cell Signaling Technology except actin).  HRP-conjugated secondary 
antibodies were purchased from Cell Signaling Technology and blots were imaged with the Syngene PXi 
imager.  Bands were quantified with ImageJ 1.48 (Wayne Rasband, National Institutes of Health). 
 
RNA Extraction and Quantitative Real-Time PCR  
For RNA extraction, animals were placed on ice and rinsed 2x with 13 ppt seawater.  For experiments 
performed at WHOI, animals were homogenized with a Teflon homogenizer in 1 mL PureZOL (Bio-Rad) 
and purified with the Aurum Total RNA Fatty and Fibrous Tissue kit (Bio-Rad) with 3-6 animals per 
sample.  RNA extractions performed at HSDM were extracted with 1 mL TRIZOL (Ambion), 
homogenized in a bullet blender homogenizer in Red Kit RNAse-free tubes for 10 minutes at level 10, 
and purified with the Direct-Zol RNA MiniPrep kit (Zymo Research) with 1-2 animals per sample.  RNA 
yield and purity were quantified using an ND-1000 spectrophotometer and cDNA was synthesized using 
the iScript cDNA Synthesis Kit (Bio-Rad) at WHOI or the ABI High Capacity cDNA Reverse 
Transcription Kit (Ambion) at HSDM. Primer pairs were designed using Primer3 and primer sequences 
are available in Table S2.  
 
Quantitative real-time PCR was performed using FastStart Universal SYBR Green Master Mix (ROX) 
(Roche) on the Step One Plus Machine (Thermo Fisher Scientific).  The conditions were as follows: 95°C 
for 10 minutes, 40 cycles of 95°C for 10 seconds followed by 60°C for 1 minute.  The qPCR efficiencies 
[Egene = (10(-1/slope)-1)*100] were determined by serial dilutions of pooled cDNA samples using cycle 
threshold (Ct) numbers for each gene analyzed.  Efficiencies for all primer pairs were between 90 and 
110%.  Specificities of all PCR reactions were confirmed by melt curve analyses.  Relative gene 
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expression changes were measured using the comparative CT method, X=2-ΔΔCT.  Target gene expression 
was normalized with 18S as the endogenous control.  
 
Immunohistochemistry 
Juvenile Nematostella (1 month old, unfed) were transferred to a 24-well plate (roughly 50 juveniles per 
well).  Prior to fixation several drops of 7% MgCl2 were added to prevent anemone contraction.  
Anemones were allowed to sit for 10 minutes before fixation.  Immunohistochemistry was performed as 
described in (107) with the following modifications: 1 mL ice-cold fixation solution was added directly to 
wells (13 ppt artificial seawater, 4% formaldehyde, 50 mM MOPs, pH 7.4, 2 mM β-glycerophosphate, 1 
mM NEM) and incubated for 20 minutes before transfer to 1.7 mL centrifuge tubes.  Samples were 
incubated for 1 hour at room temperature on rocker in fixation solution and then transferred immediately 
into MeOH.  Animals were rehydrated in a series of 5 washes of PBS/MeOH (30, 50, 70, 90, 100% PBS 
in MeOH).  Specimens were viewed and imaged with the Keyence BZ-X710 all-in-one fluorescence 
microscope. 
 
Statistics 
Data were analyzed using GraphPad PRISM, version 6.  A probability value of 0.05 was considered 
statistically significant.  
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FIGURES AND TABLES 
 
 
 
 
Figure 1 | Cartoon representing basic components and features of the mammalian ISR and their 
presence in the Nematostella genome.  (a)  eIF2α kinases are triggered by stress and phosphorylate 
eIF2α (indicated by red circle). eIF2α phosphorylation results in decreased levels of global translation and 
increased protein expression of ATF4, which further up regulates transcription of additional genes.  ATF4 
also up regulates the eIF2α-specific PP1 targeting protein, GADD34, which dephosphorylates eIF2α. 
Mammals also have another constitutively expressed eIF2α- specific PP1 targeting protein, CReP. 
Proteins with a blue star indicate orthologues that are found in the Nematostella genome (identification 
described later).  (b)  Table with ISR proteins in cartoon, indicating human and Nematostella accession 
numbers, as well as % identity between human and Nematostella orthologues, identification of which is 
described in the results section.    
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Figure 2 | Cartoon schematic showing expansion of the inducers and effectors of the ISR from yeast 
to humans portraying the general evolutionary relationships between the model species depicted.  
Figure indicates basic components of the ISR present in eukaryotic models.  Below each species is a 
simplified pathway diagram to show which ISR components and effects are known to be present.  Colors 
represent the respective proteins from the ISR pathway cartoon in figure one.  This study characterizes 
ISR components present in Nematostella. Nematostella components are depicted in gray to emphasize 
that the ISR components in Nematostella have not been characterized.  Colored Nematostella components 
indicate proteins predicted to be present based on conservation across eukaryotes.    
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Figure 3 | The three eIF2α kinases: GCN2, PERK, HRI and several ATF4 target genes are 
conserved in the Nematostella genome.  (a)  Cartoon depicting 3 kinases conserved in Nematostella 
with characteristic domains labeled.  Percentages indicate residue identity between human and 
Nematostella homologues within that domain.  Black triangles indicate conserved threonine 
phosphorylation sites involved in autophosphorylation/activation of the respective kinase.  KD, kinase 
domain; PKD, pseudo-kinase domain; HisRS, domain similar to histidyl-tRNA synthetase.  Two black 
rectangles in each kinase represent the two lobes of the kinase domain with respective identities within 
each lobe indicated.  (b)  Table indicating percent identity of residues between kinase domains of human 
and Nematostella kinases.  (c)  Table of orthologues and homologues of mammalian ISR target genes 
identified in Nematostella.   
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Figure 4 | DTT increases phosphorylation of eIF2α and transcription of characteristic ISR 
responsive genes in Nematostella.  (a)  (left panel) Adult Nematostella were treated with 4 mM DTT for 
5 hours and assayed by immunoblot for total eIF2α and eIF2α phosphorylated on Ser51 using a 
commercial phospho-specific antibody.  β-tubulin and cytoplasmic actin are shown as loading controls.  
(right panel) mRNA expression of characteristic ISR responsive genes indicated in figure from adults 
treated for 4 hours. (b)  (left panel)  Phosphorylated eIF2α and total eIF2α were measured by immunoblot 
in adults after 15 minutes, 1, 4, and 24 hours of 4 mM DTT treatment.  (right panel)  mRNA expression 
of ASNS and HERP after 2, 5, and 24 hours of 4 mM DTT treatment.  (c)  (left panel)  Phosphorylated 
eIF2α and total eIF2α were measured by immunoblot in adults after 4 hours treatment with the indicated 
DTT concentrations.  (right panel)  mRNA expression of ASNS with the indicated DTT concentrations. 
(a-c) Densitometry data are displayed below the blot and presented as the mean ratio of phosphorylated 
eIF2α/total eIF2α ± s.d. from triplicate biological replicates.  mRNA expression was normalized to 
expression of 18S mRNA and is represented as the mean of biological triplicates ± s.d.  Data in (a) are 
representative of three separate experiments and data in (b) and (c) are one experiment.  Confidence 
intervals (P value) for the effect of DTT versus untreated were determined using a one tailed Student’s t-
test.  NT, nontreated; m, minutes; h, hours.   All blots (except (c)) were also probed for actin to confirm 
equal loading and that total eIF2α levels did not change with treatment. (not shown). 
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Figure 5 | PERK inhibitor treatment slightly decreases phosphorylation of eIF2α following DTT 
treatment in Nematostella but not as strongly as in the mammalian 293T cell line.  (a) 293T were 
treated for 2 hours with the indicated concentration of inhibitor in the presence or absence of 4 mM DTT 
for the second hour.  Total eIF2⍺ and phosphorylated eIF2⍺ were assayed by immunoblot.  (b) Adult 
Nematostella were treated for 2 or 4 hours with the indicated concentration of inhibitor in the presence or 
absence of 4 mM DTT for the last 15 minutes.  Total eIF2⍺ and phosphorylated eIF2⍺ were assayed by 
immunoblot.  (a-b)  Densitometry data are displayed below the blot and data are representative of one 
experiment. 
 
 
 
 
 
 
Figure 6 | HF increases phosphorylation of eIF2α and induces ASNS and HERP gene expression in 
juvenile Nematostella.  (left panel)  Juvenile (1 month old, not yet fed) Nematostella were treated with or 
without 10 uM HF for 4 hours and assayed by immunoblot for phosphorylated and total eIF2⍺.  (right 
panel)  mRNA expression of ASNS and HERP from juveniles under the same conditions as on the left. 
Densitometry data are displayed below the blot and presented as the mean ratio of phosphorylated 
eIF2⍺/total eIF2⍺ ± s.d. from duplicate biological replicates.  mRNA expression was normalized to 
expression of 18S mRNA and is represented as the mean of duplicate biological replicates ± s.d.  Data are 
representative of two (left) and three (right) separate experiments.  Confidence intervals (P value) for the 
effect of HF versus untreated (DMSO) were determined using a one tailed Student’s t-test.  All blots were 
also probed for actin to confirm equal loading and that total eIF2⍺ levels did not change with treatment. 
(not shown).	
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Figure 7 | Temperature, increased salinity, and copper exposure induce ISR readouts in adult 
Nematostella.  (a-d)  Temperature.  (a)  Phosphorylated and total eIF2⍺ levels assayed by immunoblot 
after exposure to room temperature (22°C) or 37°C for durations ranging between 30 minutes to 6 hours 
indicated in figure.  (b)  Phosphorylated and total eIF2⍺ levels assayed by immunoblot after exposure to 
37°C for durations ranging between 10 minutes and 2 hours.  (c)  Phosphorylated and total eIF2⍺ levels 
assayed by immunoblot after exposure for 30 minutes to low 4°C and warm 37°C for 30 minutes.  (d)  
mRNA expression of ASNS, HERP, and BiP 3.5 hours after 30 minute exposure to 37°C.  (e)  Salinity.  
mRNA expression of ASNS and HERP after exposure to 0, 13, or 50 ppt artificial seawater for 4 hours.  
(f)  mRNA expression of ASNS and HERP after exposure to 20 µM copper for 4 hours.  (a-c) 
Densitometry data are displayed below the blot and presented as the mean ratio of phosphorylated 
eIF2⍺/total eIF2⍺ ± s.d. from triplicate biological replicates.  mRNA expression was normalized to 
expression of 18S mRNA and are represented as the mean of biological triplicates ± s.d.  Data in (a-c, f) 
are representative of one experiment and data in (d,e) are representative of two separate experiments.  
Confidence intervals (P value) for the effect of treatment versus untreated were determined using a one 
tailed Student’s t-test.  All blots were also probed for actin to confirm equal loading and that total eIF2⍺	
levels did not change with treatment. (not shown). 
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Figure S1 | Phylogram of maximum likelihood analysis of eIF2α kinases from 13 eukaryotic 
genomes. Saccharomyces cerevisiae (Sc), Amphimedon queenslandica (Aq), Acropora digitifera (Ad), 
Nematostella vectensis (Nv), Hydra vulgaris (Hv), Caenorhabditis elegans (Ce), Drosophila 
melanogaster (Dm), Ciona intestinalis (Ci), Strongylocentrotus purpuratus (Sp), Branchiostoma floridae 
(Bf), Petromyzon marinus (Pm), Danio rerio (Dr), and Homo sapiens (Hs). Blue shaded lines indicate 
vertebrate species, black lines indicate non-vertebrate deuterostomes and protostomes, red shaded lines 
indicate cnidarian species, yellow indicates sponge, and green indicates yeast. Node labels represent 
percentage of 1,000 bootstraps and labels on the far right indicate kinase type.  
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Figure S1 | Phylogram of maximum likelihood analysis of eIF2α kinases from 13 eukaryotic genomes.  Saccharomyces cerevisiae (Sc), 
Amphimedon queenslandica (Aq), Acropora digitifera (Ad), Nematostella vectensis (Nv), Hydra vulgaris (Hv), Caenorhabditis elegans (Ce), 
Drosophila melanogaster (Dm), Ciona intestinalis (Ci), Strongylocentrotus purpuratus (Sp), Branchiostoma floridae (Bf), Petromyzon marinus 
(Pm), Danio rerio (Dr), and Homo sapiens (Hs).  Blue shaded lines indicate vertebrate species, black lines indicate non-vertebrate deuterostomes 
and protostomes, red shaded lines indicate cnidarian species, yellow indicates sponge, and green indicates yeast.  Node labels represent 
percentage of 1,000 bootstraps and labels on the far right indicate kinase type.      
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Figure S1.  Alignment of eIF2α proteins from 7 metazoan species indicating high similarity between amino acid sequences and conservation of 
serine phosphorylation site central to the ISR. Serine phosphorylation site is indicated by red star.  Full species names are the following: Homo 
sapiens, Danio rerio, Drosophila melanogaster, Anopheles gambiae, Caenorhabditis elegans, Nematostella vectensis, and Trichoplax adhaerens. 
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Figure S2.  Phylogram of maximum likelihood analysis of eIF2α kinases from the following 13 eukaryotic genomes: Saccharomyces cerevisiae 
(Sc), Amphimedon queenslandica (Aq), Acropora digitifera (Ad), Nematostella vectensis (Nv), Hydra vulgaris (Hv), Caenorhabditis elegans 
(Ce), Drosophila melanogaster (Dm), Ciona intestinalis (Ci), Strongylocentrotus purpuratus (Sp), Branchiostoma floridae (Bf), Petromyzon 
marinus (Pm), Danio rerio (Dr), and Homo sapiens (Hs).  Blue shaded lines indicate vertebrate species, black lines indicate non-vertebrate 
deuterostomes and protostomes, red shaded lines indicate cnidarian species, yellow indicates sponge, and green indicates yeast.  Node labels 
represent percentage of 1,000 bootstraps and labels on the far right indicate kinase type.    
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Figure S2 | Phylogram of maximum likelihood analysis of bZIP transcription factor family from 
eight eukaryotic genomes.  Saccharomyces cerevisiae (Sc), Monosiga brevicollis (Mb), Nematostella 
vectensis (Nv), Caenorhabditis elegans (Ce), Drosophila melanogaster (Dm), Ciona intestinalis (Ci), 
Danio rerio (Dr), and Homo sapiens (Hs).  Tree is divided into four sections (a-d) for easier viewing.  
Blue lines indicate human proteins, red lines indicate Nematostella proteins, and green indicates proteins 
of interest.  DDIT3 represents human CHOP.  Node labels represent percentage of 1,000 bootstraps and 
labels on far right indicate bZIP family.  Red circle indicates families of interest due to their involvement 
in the ISR. 
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Figure S2 | Phylogram of maximum likelihood analysis of bZIP transcription factor family from eight eukaryotic genomes.  
Saccharomyces cerevisiae (Sc), Monosiga brevicollis (Mb), Nematostella vectensis (Nv), Caenorhabditis elegans (Ce), Drosophila melanogaster 
(Dm), Ciona intestinalis (Ci), Danio rerio (Dr), and Homo sapiens (Hs).  Tree is divided into 4 sections (a-d) for easier viewing.  Blue lines 
indicate human proteins, red lines indicate Nematostella proteins, and green indicates proteins of interest.  DDIT3 represents human CHOP.  
Node labels represent percentage of 1,000 bootstraps and labels on the far right indicate bZIP family.  Red circle indicates families of interest due 
to their involvement in the ISR.  
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Figure S3.  Phylogram of maximum likelihood analysis of bZIP transcription factor family from the following eight eukaryotic genomes: 
Saccharomyces cerevisiae (Sc), Monosiga brevicollis (Mb), Nematostella vectensis (Nv), Caenorhabditis elegans (Ce), Drosophila melanogaster 
(Dm), Ciona intestinalis (Ci), Danio rerio (Dr), and Homo sapiens (Hs).  Tree is divided into four sections, A-D, for easier viewing.  Blue shaded 
lines indicate Homo sapiens proteins, red shaded lines indicate N. vectensis proteins, green indicates proteins of interest.  DDIT3 represents Homo 
sapiens CHOP.  Node labels represent percentage of 1,000 bootstraps and labels on the far right indicate bZIP family.  Red circle indicate 
families of interest due to their known contributions to the ISR.    
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Figure S3 | Localization of peIF2α in juvenile Nematostella. Whole mount immunofluorescence was 
performed with peIF2α antibody on juveniles treated with or without 500 uM DTT for 30 minutes. Each 
row within each panel represents a single animal. peIF2α was probed with FITC secondary (green) and 
nuclei are DAPI stained (blue). (a) No DTT treatment. (b) DTT treatment. (c) No DTT treatment or 
primary antibody. (d) DTT treatment and no primary antibody. (e) No DTT treatment or secondary 
antibody. (f) DTT treatment and no secondary. (g) Low magnification. (h) High magnification of 
individuals from panel (b) showing cytoplasmic staining. 
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ISR$Protein
Human$NCBI
Accession$#:
Nematostella
JGI$ID:
Tulin$et.$al
Transcriptome
Identifier:
Nematostella
sequence$used
in$study Additional$Species$Mentioned:
eIF2α NP_004085.1 185797 JGI
GCN1 NP_006827.1 168356,$20230
comp4420_c0_seq1,$
comp8202_c0_seq1
concatenated$
Tulin
GCN2 EAW92388.1 30010 JGI
S.+cerevisiae:$YDR283V,$$D.+melanogaster:$FBpp0085148,$H.+vulgaris:$$
XP_002154172.2,$A.+digitifera:$aug_v2a.04771.t1,+C.+elegans:$DC2.7a,$$C.+
intestinalis:$ENSCINP00000035877,$$S.+purpuratus:$$XP_785160.3,$B+
floridae:$XP_002613455.1,$
P.+marinus:++ENSPMAP00000007704,+D.+rerio:$$ENSDARP00000098667$$$$$$$$$
PERK AAF61199.1 238489 JGI
A.+queenslandica:+PAC:15713749,$H.+vulgaris:$XP_004208197.1,$A+
digitifera:$aug_v2a.06243.t1,$C.+elegans:$F46C3.1,$C.+intestinalis:+
ENSCINP00000006293,$S.+purpuratus:+$XP_792135.3,+B.+floridae:+$
XP_002603649.1,$P.+marinus:+ENSPMAP00000006894,$D.+rerio:+
ENSDARP00000120826,$D.+melanogaster:$FBpp0078417$$$$$$$$$$$$$$$$$$$
HRI AAF70289.1 200396 JGI
H.+vulgaris:$XP_002158812.1,$S.+purpuratus:$$XP_003728812.1,$B.+
floridae:$XP_002597671.1,$C.+intestinalis:$ENSCINP00000025661,$D.+rerio:+
ENSDARP00000002313,$P.+marinus:$$ENSPMAP00000002333$$$$$$$$
PKR P19525.2 Z Z Z D.+rerio:$ENSDARP00000090291$
ATF4 NP_001666.2 sca303 comp3036_c0_seq1 Tulin T.+adhaerens:$TriadT63596,$A.+queenslandica:$PAC:15724215
CHOP P35638.1 Z Z Z Z
GADD34 O75807.1 238227 JGI
CreP NP_116222.4 Z Z Z Z
SNAT2 Q96QD8.2 83628 comp4370_c0_seq2 Tulin
xCT Q9UPY5.1 167234 JGI
TRB3 Q96RU7.2 164837 JGI
CHAC1 Q9BUX1.2 208105 JGI
BiP$(GRP78) P11021.2 216823 JGI +D.+melanogaster:$NP_611863.1
ASNS AAA52756.1 163815 JGI
HERP1 Q15011.1 29773 comp8577_c0_seq1 Tulin
CATZ1 P30825.1 Z Z Z Z
VEGF AAA35789.1 Z Z Z Z
REDD1 Q9NX09.1 Z Z Z Z
Gene Primer Primer(Sequence
NvASNS forward TGTAGCTGCTGCACGTAAGG
reverse GCAACCAGGTACATCGGAAC
NvHERP forward CATAACATGGGATTGCCACA
reverse GTTGCTGGTTGACAGGAGGT
NvCHAC1 forward TTGCAGATAGTGTCGGCTCA
reverse TTCGACTTGAGGGACTTTGG
NvTRIB3 forward TGTCACAGTTCGGGTGTTGT
reverse GCAGCCATGTTTGTCCTCA
NvSNAT2 forward CAGCATCAACCTCAGCCTTC
reverse GAGCAATCGTCCAAACCACT
NvxCT forward AAACTTCTTGCGGCTGTCTG
reverse AAGCTGCCAGTGAAACCTTG
NvBiP forward GAGCTCTCAGTACACAGCACCA
reverse ACTTTCTGGACGGGCTTCA
NvActin forward TACGAGTTGCCTGATGGACA
reverse TACCCAGAAAGGAGGGCTGA
Nv18S* forward GACTCAACACGGGGAAACTC
reverse GCACCACCACCCATAGAATC
*(sequences(from(Tarrant(Lab
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ISR$Protein
Human$NCBI
Accession$#:
Nematostella
JGI$ID:
Tuli $et.$al
Transcriptome
Identifier:
Nematostella
sequence$used
in$study Additional$Species$Mentioned:
eIF2α P_004085.1 185797 JGI
GCN1 NP_006827.1 168356,$20230
comp4420_c0_seq1,$
comp8202_c0_seq1
concatenated$
Tulin
GCN2 EAW92388.1 30010 JGI
S.+c revisiae:$YDR283V,$$D.+melanogaster:$FBpp0085148,$H.+vulgaris:$$
XP_002154172. ,$A.+digitifera:$aug_v2a.04771.t1,+C.+elegans:$DC2.7a,$$C.+
intestinali :$ENSCINP00 358 ,$$S.+purpuratus:$$XP_78516 .3,$B+
florida :$XP_002613455.1,$
P.+marinus:++ENSPMAP00000007704,+D.+rerio:$$ENSDARP00000098667$$$$$$$$$
PERK AAF61199.1 238489 JGI
A.+queenslandica:+PAC:15713749,$H.+vulgaris:$XP_004208197.1,$A+
digitifera:$aug_v2a.06243.t1,$C.+elegans:$F46C3.1,$C.+intestinalis:+
E SCINP0 06293,$S.+purpuratus:+$XP_792135.3,+B.+floridae:+$
XP_002603649.1,$P.+marinus:+ENSPMAP00000006894,$D.+rerio:+
ENSDARP000 120826,$D.+melanogaster FBpp0078417$$$$$$$$$$$$$$$$$$$
HRI AAF7 289.1 200 96 JGI
H.+vulgaris:$XP_002158812.1,$S.+p rpuratus:$$X _ 3728812.1, B.+
floridae XP_002597671.1,$C.+intestinalis:$ENSCINP00000025661,$D.+rerio:+
ENSDARP0000000231 ,$P.+marin s:$$ENSPMAP00000002333$$$$$$$$
PKR P19525.2 Z Z Z D.+rerio:$ENSDARP00000090291$
TF4 NP_001666.2 sca303 comp3036_c0_seq1 Tulin T.+adhaerens:$TriadT63596,$A.+queenslandica:$PAC:15724215
CHO 35638.1 Z Z Z Z
GADD34 O75807.1 2382 7 JGI
CreP NP_116222.4 Z Z Z Z
SNAT2 Q96QD8. 83628 comp4370_c0_seq2 Tulin
xCT UPY5.1 167234 J I
TRB3 Q96RU7 164837 J I
CHAC1 Q9BUX1.2 208105 J I
BiP$(G 78) P11021.2 21682 JGI +D.+melanogaster:$NP_611863.1
ASNS AAA527 6.1 163815 JGI
HERP1 Q15011.1 29773 comp8577_c0_seq1 Tulin
CATZ1 P30825.1 Z Z Z Z
VEGF AAA35789.1 Z Z Z Z
REDD Q9NX09.1 Z Z Z Z
Gene Primer Primer(Sequence
NvASNS forward TGTAGCTGCTGCACGTAAGG
reverse GCAACCAGGTACATCGGAAC
NvHERP forward CATAACATGGGATTGCCACA
reverse GTTGCTGGTTGACAGGAGGT
NvCHAC1 forward TTGCAGATAGTGTCGGCTCA
reverse TTCGACTTGAGGGACTTTGG
NvTRIB3 forward TGTCACAGTTCGGGTGTTGT
reverse GCAGCCATGTTTGTCCTCA
NvSNAT2 forward CAGCATCAACCTCAGCCTTC
reverse GAGCAATCGTCCAAACCACT
NvxCT forward AAACTTCTTGCGGCTGTCTG
reverse AAGCTGCCAGTGAAACCTTG
NvBiP forward GAGCTCTCAGTACACAGCACCA
reverse ACTTTCTGGACGGGCTTCA
NvActin forward TACGAGTTGCCTGATGGACA
reverse TACCCAGAAAGGAGGGCTGA
Nv18S* forward GACTCAACACGGGGAAACTC
reverse GCACCACCACCCATAGAATC
*(sequences(from(Tarrant(Lab
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CHAPTER 3 
 
The evolutionarily conserved protein GCN1 is a novel branch point in the mammalian AAR 
pathway   
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INTRODUCTION 
 
Nutrient sensing pathways have evolved roles in cellular protection 
The ability to successfully respond to environmental stimuli, such as changing nutrient conditions, is 
essential to an organism’s survival. Signaling pathways that sense nutrient availability are also integral to 
cellular defense and tissue homeostasis (1-4). A well-recognized example of adaptation to nutrient 
limitation occurs in bacteria and utilizes the protein synthetic machinery for signal generation. Stringent 
control, first described in E. coli, but also found in plant plastids, detects amino acid depletion by sensing 
non-aminoacylated, or uncharged, tRNA and responds by comprehensive transcriptional reprogramming 
to induce growth arrest, upregulate survival genes and increase virulence in pathogenic bacteria (5, 6). 
Induction of nutrient sensing pathways is a phylogenetically conserved feature in the control of lifespan in 
whole organisms such as yeast, C. elegans, and Drosophila, and plays a key role in the control of aging 
and age-related diseases (7, 8). Amino acid sensing pathways, like mTOR and the AAR pathway, also 
participate in immuno-regulation (9, 10).  The mammalian immune system protects tissue and organ 
structural integrity by balancing protective inflammatory response to a stress with its timely resolution. 
During injury or infection, tissue and immune homeostasis are shifted; failure to restore balance can result 
in sustained inflammatory cytokine signaling, pathologic inflammation and tissue damage (11). 
Mammalian immune regulation has evolved to utilize the induced breakdown of amino acids through 
transcriptional upregulation of amino acid-degrading enzymes (and the concomitant induction of the AAR 
pathway), to limit hyper-inflammatory innate responses and promote tolerance to self (2, 12, 13). 
 
HF’s therapeutic effects depend upon activation of the AAR pathway  
Our lab became interested in the connection between the activation of nutrient stress response pathways 
and the control of tissue inflammation when the lab solved the molecular target of the small molecule 
therapeutic, HF (14).  HF inhibits the catalytic activity of glutamyl-prolyl-tRNA synthetase (EPRS), 
thereby activating the nutrient-sensing AAR pathway (14, 15). Under conditions of amino acid limitation, 
aaRSs, the cellular enzymes that charge amino acids into cognate tRNA, cannot perform their function 
and non-aminoacylated or uncharged tRNA accumulates.  By inhibiting the PRS activity of EPRS, HF 
acts as amino acid restriction mimetic, using the cell’s protein synthetic machinery to generate the 
accumulation of uncharged tRNA (14). We now know that the addition of HF to cytokine-stimulated cells 
selectively inhibits inflammatory responses in diverse cell types, and that these cellular responses to HF 
treatment can occur in cells that lack the signature AAR pathway effector GCN2 (Kim et al, manuscript in 
preparation). Additionally, we know that borrelidin, a TRS inhibitor, can reproduce many of the key 
therapeutic tissue responses of HF treatment (Kim et al, manuscript in preparation). The ability of these 
inhibitors to induce therapeutic effects in cells that lack GCN2 indicates both the existence of a previously 
unrecognized branch point in the mammalian AAR pathway, and the presence of a novel sensor of 
uncharged tRNA in mammalian cells.  
 
HF inhibits an inflammatory program involved in chronic inflammatory diseases and RA 
HF inhibits an inflammatory program involved in chronic inflammatory disease and rheumatoid arthritis 
(RA), including inhibition of pro-inflammatory T-cell differentiation and transcription of pro-
inflammatory mediators (16) (Kim et al, manuscript in preparation).  An essential component of any 
protective immune response is proper regulation, which includes downregulation of the immune response.  
In chronic inflammatory disease, like RA, immune responses are dysregulated and a positive feedback 
loop of signals activates and perpetuates a tissue-damaging program (11).  T helper 17 (Th17) cells, a pro-
inflammatory T-cell subset, are broad mediators of autoimmunity and implicated in RA (17, 18).  Via 
AAR induction, HF inhibits Th17 differentiation, which can be rescued by addition of proline and 
mimicked by amino acid depletion (16).  RA is a chronic autoimmune inflammatory disease that 
primarily attacks synovial joints exhibiting synovial inflammation, proliferation of synovial tissues, and 
destruction of cartilage and bone.  Fibroblast-like synoviocytes (FLS), resident mesenchymal cells of the 
synovium (the tissue lining of the edges of the joint space), play an important role in the pathogenesis of 
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RA (19, 20).  In RA, activation of FLS by cytokines and other soluble factors leads to FLS production of 
molecules that recruit, retain, and activate cells of the immune system and other joint cells, leading to the 
promotion of ongoing inflammation and tissue damage (20).  Activated FLS further contribute to tissue 
damage by the upregulation and secretion of matrix degrading enzymes.  Our lab has found that HF 
treatment significantly downregulates transcription of many of these pro-inflammatory and tissue 
remodeling mediators in both TNF-α activated FLS and other cytokine-stimulated cell types implicated in 
inflammatory and fibrotic disease (Kim et al, manuscript in preparation).  
 
These observations point to a GCN2-independent pathway induced by uncharged tRNA in mammalian 
cells but what proteins mediate this pathway are unknown.  The conservation of the AAR pathway across 
eukaryotes provides two proteins as candidate mediators of this novel pathway, GCN1 and ABCF3. In 
yeast these proteins function upstream of GCN2: where GCN1 is required for GCN2 activation by 
uncharged tRNA and the yeast ortholog of ABCF3, GCN20, is required for full AAR pathway induction 
(21-27).  In the nematode, C. elegans, GCN1 and ABCF3 mediate apoptotic functions independently of 
GCN2 (28).  The functions of these proteins remain unknown in mammalian cells.  To investigate 
whether GCN1 and ABCF3 represent a branch point within the AAR pathway, mediating GCN2-
dependent and independent pathways I first tested whether GCN1 and ABCF3 are required for AAR 
signaling in mammalian cells.  I did this by assessing AAR pathway readouts in HF-treated GCN1 and 
ABCF3 knockout cell lines.  Since GCN1 but not ABCF3 was required for AAR pathway activation, I 
next tested whether GCN1 was required for GCN2-independent therapeutic transcriptional effects in HF-
treated GCN1-knockdown FLS.  This showed that GCN1 was required for GCN2-independent effects, 
revealing GCN1 as a branch point in the mammalian AAR pathway.  
  
How GCN1 functions and what additional functions this GCN2-independent pathway may mediate are 
unknown.  GCN1 is presumed to function at the ribosome due to its functional role described in yeast, but 
its localization has not been characterized (23).  GCN1 has not been studied in mammalian cells but has 
been identified as a putative interactor with a large set of proteins seemingly distinct from its role at the 
ribosome (29-31). These interactors include proteins known to localize to the nucleus such as components 
of the mediator complex (31-40).  These observations suggest that GCN1 may function away from the 
ribosome, potentially mediating GCN2-independent functions by interacting with proteins in other cell 
compartments, such as the nucleus.  HF treatment could regulate GCN1 location, moving GCN1 from the 
ribosome into the nucleus.  To determine whether GCN1 may be present elsewhere in the cell and if HF 
regulates GCN1 location, I biochemically fractionated cells treated with and without HF.  Since GCN1 
was present in multiple cell fractions and its distribution changed with HF, I then tried to see if GCN1 
was located in the nucleus by microscopy with and without HF treatment.  Additionally, I 
immunoprecipitated GCN1 from isolated nuclei, and identified co-precipitating proteins by mass 
spectrometry analysis, both to confirm previously identified GCN1 nuclear interactors and identify GCN1 
nuclear interactors in an unbiased manner. 
 
RESULTS 
 
GCN1, but not ABCF3, is required for GCN2 phosphorylation and the AAR transcriptional 
response in mammalian cells 
To ask whether GCN1 and ABCF3 represent a branch point in the mammalian AAR, we first needed to 
determine if these proteins are required for the AAR in mammals.  In yeast, GCN1 and GCN20 function 
upstream of GCN2, and are required for GCN2 phosphorylation by uncharged tRNA (21, 22).  These 
genes are conserved in the mammalian genome and in C. elegans, GCN1 and ABCF3 mutants exhibit 
decreased peIF2α levels (28).  Overexpression of a fragment of mammalian GCN1 analogous to the 
portion of yeast GCN1 that binds GCN2 in yeast, inhibits AAR activation in a mammalian cell (41).  
Together these observations strongly suggest that GCN1 and ABCF3 are required for the AAR in 
mammals, but this has not been tested.  To determine if GCN1 and ABCF3 are required, CRISPR-
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mediated knockout human colon carcinoma HCT116 cell lines of GCN2, GCN1, and ABCF3 were 
assayed for AAR induction upon HF treatment by measuring phosphorylated GCN2 and eIF2α levels.  In 
HF treated knockout GCN2 and GCN1 cell lines, GCN2 and eIF2α phosphorylation was absent 
establishing that GCN1 is indeed required for AAR activation in mammals (Fig 1a).  Unexpectedly, 
GCN2 and eIF2α phosphorylation were not absent or decreased in ABCF3 knockout cells, demonstrating 
that ABCF3 is not required for AAR induction in mammals (Fig 1a).  In yeast, GCN1 deletion decreases 
GCN20 levels, but this is not observed in GCN1 knockout HCT116 cell lines (22) (Fig 1a). To determine 
if GCN1 is required in other cell types, we knocked down GCN1 protein levels by shRNA in HeLa, the 
cell line used to identify putative GCN1 protein interactors in previous studies, and measured 
phosphorylated GCN2 and eIF2α levels upon HF treatment.  GCN1 knockdown HeLa also showed 
decreased AAR activation compared to wildtype upon HF treatment, which was rescued by ectopic 
expression of shRNA-resistance GCN1 (Fig S2a).  Similarly, shRNA-mediated GCN1 knockdown in the 
transformed FLS cell line, K4, the cell line in which our lab has found HF regulated GCN2-independent 
transcriptional effects, decreased HF phosphorylation of GCN2 and eIF2α (data not shown). Together 
these results demonstrate that GCN1 is required for the GCN2-eIF2α portion of the AAR in mammals. 
 
The GCN2-eIF2α-ATF4 pathway of the AAR mediates adaptive gene transcription including amino acid 
biosynthetic genes and genes involved in negative feedback regulation of the pathway.  To confirm 
whether GCN1 and ABCF3 are required for the transcriptional program of the AAR in mammals, 
knockout GCN2, GCN1, and ABCF3 HCT116 cell lines were assayed for mRNA expression of 
characteristic AAR transcriptional targets upon HF treatment.  As expected, induction of TRB3, ASNS, 
and ATF3 by HF was absent in GCN1 null cells mirroring pGCN2 results, while in ABCF3 null cells 
induction by HF was unchanged relative to wildtype (Fig 1b), establishing that GCN1, but not ABCF3 is 
required for the mammalian AAR. 
 
Several HF therapeutic transcriptional effects require GCN1, but not GCN2 
GCN2 is the only known sensor of uncharged tRNA in the eukaryotic cell and the GCN2-eIF2α-ATF4 
pathway is the only known mediator of the uncharged tRNA signal. Our lab has found, however, that a 
subset of HF therapeutic effects is GCN2-independent, including transcriptional inhibition of a set pro-
inflammatory mediators induced by TNFα in K4 FLS.  Since we now know GCN1 is an upstream 
mediator of the AAR in mammalian cells and represents a logical candidate mediator of GCN2-
independent effects, we can ask if GCN1 is required for these GCN2-independent effects.  This question 
was first tested by Yeon-Jin Kim by testing if known GCN2-independent transcriptional effects upon HF 
treatment and TNFα stimulation were present in shRNA-mediated GCN1 knockdown K4 cells.  I repeated 
these observations with Halofuginol (HFol), a less cytotoxic analog of HF with potential for drug 
development (42).  HFol exhibits the same therapeutic effects of HF at similar doses, but exhibits fewer 
of the side effects that have hampered clinical use of HF (42) (Fig 2b, c). HFol treatment inhibited 
mRNA expression of several pro-inflammatory mediators, including CXCL10, MMP13, and IDO1, in 
shRNA-mediated scrambled control and GCN2 knockdown K4 cells, but not in GCN1 knockdown cells 
(Fig 2a, c).  Knockdown of TRIB3 expression in GCN2 and GCN1 knockdown cells confirmed that the 
GCN2-eIF2α-ATF4 transcriptional pathway was well knocked down in these cells (Fig 2a).  HF 
inhibition of these pro-inflammatory mediators is absent with proline addition and inhibition of these pro-
inflammatory mediators is recapitulated by borrelidin treatment, demonstrating that these GCN2-
independent, GCN1-dependent transcriptional effects are a result of HF production of uncharged tRNA 
(Kim et al, manuscript in preparation).  Notably, similar experiments in shRNA-mediated ABCF3 
knockdown K4 cells showed that ABCF3 is not required for these effects as expected from the previous 
results in knockout HCT116 cells (Kim et al, manuscript in preparation).  Thus GCN1 represents an 
upstream branch point in the mammalian AAR pathway.   
 
Several extraction methods show presence of GCN1 in cell fractions with nuclear components 
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In yeast, GCN1 is known to physically associate with polysomes, and this is where GCN1’s only 
identified function occurs with respect to GCN2, but in yeast and mammals GCN1 is putatively 
associated with numerous nuclear proteins (23, 25, 26).  This suggests GCN1 may function elsewhere in 
the cell.  To determine if GCN1 is present in additional cell compartments, both HeLa and K4 cells were 
fractionated by several methods (Fig 3).  Fractionation using the Thermo Subcellular Protein 
Fractionation Kit for Cultured Cells showed that a large fraction of GCN1 is present in fractions 
containing nuclear components (Fig 3a).  Digitonin extraction, which selectively permeabilizes the cell 
membrane extracting primarily the cytoplasm, followed by an NP-40/high salt extraction of the remaining 
cellular material in HeLa and K4, showed a consistent pattern.  Strong GCN1 signal remained in the NP-
40/high salt fraction in which membranous and nuclear fractions of the cell are extracted (Fig 3b).  A 
traditional Dignam extraction also showed a fraction of GCN1 in the high salt extract after hypotonic 
extraction (Fig 3b).  Cell fractionation shows that GCN1 is present in fractions associated with nuclear 
proteins, but cannot tell us whether GCN1 is present in the nucleus.  GCN1 localization within the cell 
will be further analyzed by immunofluorescence later in the chapter.  These results suggest that GCN1 is 
present in multiple locations within the cell. 
 
HF treatment shifts GCN1 localization 
To determine if the AAR regulates GCN1 localization we tested if HF treatment changes the distribution 
of GCN1 within the cell.  K4 cells were treated with and without HF and sequentially extracted; first by 
digitonin to selectively permeabilize the cell membrane extracting the cytoplasm, then by NP-40 to 
extract membranous cell components including the ER, then by high salt to extract nuclear components, 
and then finally by SDS-containing RIPA buffer to solubilize most of the remaining material.  HF 
increased GCN1 levels in the digitonin fraction, with a concomitant decrease in GCN1 levels in the NP-
40 and high salt fractions (Fig 4).  This indicates that the AAR regulates GCN1 localization in the 
mammalian cell. 
 
Immunofluorescence does not distinguish a nuclear GCN1 fraction  
To determine whether GCN1 is present in the nucleus we characterized GCN1 localization in the 
mammalian cell by immunofluorescent staining of GCN1 by confocal microscopy.  Staining of both 
HeLa and K4 cells with Novus GCN1 commercial antibody (same antibody used in immunoblotting) 
exhibited a nuclear signal, which was clearly visible after digitonin extraction, but was not decreased in 
shRNA-mediated GCN1 knockdown HeLa (Fig 5a).  This suggested the nuclear signal was either non-
specific or resistant to shRNA knockdown.  Staining with a second commercial antibody (Sigma) 
exhibited no nuclear signal in either cell type and was completely absent in GCN1 knockdown HeLa (Fig 
5b).  It is possible these antibodies recognize different forms of GCN1 since they recognize different parts 
of GCN1.  Comparison of these two commercial GCN1 antibodies by western showed different patterns 
across biochemical fractions (Fig S3a).  Since we were unable to generate GCN1 knockout HeLa or K4 
cells, which would have provided the definitive control to determine signal specificity, live-cell imaging 
of cells overexpressing a tdTomato-GCN1 fusion construct was performed to determine which antibody 
pattern was replicated.  tdTomato-GCN1 expression was cytoplasmic (Fig S3b).  Immunofluorescent 
staining of transiently expressed Flag-tagged GCN1 exhibited a similar pattern (not shown).  Tagged 
GCN1 and endogenous GCN1 had similar distribution patterns across cellular fractions by immunoblot 
analysis suggesting neither tag significantly altered GCN1 distribution (Fig S3a).  Finally since we were 
able to generate GCN1 knockout HCT116 cells, comparison of immunofluorescent staining by the two 
commercial GCN1 antibodies in these cells confirmed that the nuclear signal of the first antibody was 
likely non-specific.  The nuclear signal when stained by Novus antibody was present in GCN1 knockout 
HCT116 cells (Fig 5c).  There could be differences in different cell types but in combination with the 
previous data this seems unlikely, supporting cytoplasmic localization of GCN1.  No change could be 
seen in HeLa or K4 cells treated with HF by immunofluorescent staining with either antibody (Fig 6).   
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Nuclear IP-MS identifies putative GCN1 interactors and reveals non-specificity of commercial 
antibody 
To determine what GCN1 may be interacting with in the nucleus, we pulled down GCN1 with 
commercial antibody from HeLa nuclear lysate in collaboration with the Robin Reed lab, and identified 
interacting proteins by mass spectrometry.  The Reed lab has extensive experience isolating intact and 
functional endogenous nuclear complexes without overexpression, and have extensive control datasets for 
comparison to filter out non-specific background.  143 proteins were unique to our GCN1 IP and the 18 
most abundant proteins are shown in Table 1.  There was little overlap with previously documented 
GCN1 interactors, but 2 mediator subunits were present, albeit only single peptides were detected (not 
shown).  Two interesting groups of interactors emerged including an NFkB1 complex and a Zeb1 
complex. In light of GCN1’s role in FLS inflammatory gene expression presented in this chapter and 
known therapeutic activities of HF, the NFkB1 and Zeb1 complexes were particularly interesting as 
nuclear regulators of inflammation and ECM remodeling.  NFkB1 is a major regulator of immune 
response that forms a complex with MAP3K8 and ABIN-2, which were also pulled down by GCN1 
immunoprecipitation (43).  Zeb1 is a transcriptional repressor that forms a complex with Ctbp1 and 
Ctbp2, which were also pulled down (44).  The Zeb1 and NFkB1 results were confirmed by pull down of 
GCN1 with the same commercial GCN1 antibody from HeLa nuclear lysates with subsequent 
immunoblotting for Zeb1 and NFkB1 (Fig 7a).  However, immunoprecipitation of Zeb1 and NFkB1 with 
commercial antibodies was unable to co-precipitated GCN1.  Likewise pull down of GCN1 with GCN1 
sera generated by our lab was unable to co-precipitate Zeb1 or NFkB1 (Zeb1: not shown, NFkB1:Fig 7b).  
This suggests that these antibodies either impede the respective interaction or commercial GCN1 antibody 
directly recognizes and pulls down Zeb1 and NFkB1.  Ectopic expression of Zeb1 with subsequent 
immunoblot analysis of the cell lysate with commercial GCN1 antibody shows that the commercial 
GCN1 antibody directly recognized Zeb1, suggesting that the commercial GCN1 antibody is non-specific 
(Fig 7c).  Together with the immunofluorescence results suggesting this antibody has non-specific signal, 
we do not know which of these proteins are true GCN1 interactors or artifacts of antibody non-specificity. 
Additional experiments with optimized conditions will be required to confirm which of these proteins are 
GCN1 interactors.   
 
DISCUSSION   
 
GCN1 is required for GCN2-dependent and -independent HF effects in mammals 
The high degree of evolutionary conservation of the AAR pathway throughout eukaryotes suggests GCN1 
and ABCF3 as candidate mediators of the GCN2-independent effects of HF treatment. In functional 
studies in yeast, these genes map upstream of GCN2 and are required for AAR pathway activation. Here I 
show that in mammalian cells, as in yeast, GCN1 is required for AAR pathway function. Significantly, I 
also show that GCN1 is required for key GCN2-independent responses to HF-treatment. These 
observations describe a novel response to nutrient stress in mammalian cells, in that aaRS-inhibition is 
producing tissue responses that require GCN1 but that do not require the recognized sensor of uncharged 
tRNA and the signature AAR pathway effector GCN2.  These data establish GCN1 as a branch point in 
the mammalian AAR pathway. 
 
ABCF3 is not required for AAR pathway signaling 
Unexpectedly, GCN2 and eIF2α phosphorylation were not absent or decreased in ABCF3 knockout cells 
indicating ABCF3 is not required for AAR pathway induction in mammals.  Additional experiments also 
suggested ABCF3 was not required for GCN2-independent GCN1 effects (Kim et al, manuscript in 
preparation).  In yeast, GCN20 is required for full AAR pathway activation: deletion of GCN20 does not 
eliminate AAR pathway activation, but impairs GCN4 de-repression (yeast ATF4 equivalent) and reduces 
phospho-eIF2α levels (22).  Although its functional mechanism is not fully understood, in yeast and in C. 
elegans, GCN20/ABCF3 physically interacts with GCN1 via a conserved N-terminal domain (22, 28). In 
yeast, data suggest that GCN20 stabilizes the interaction between GCN1 and GCN2, and is required for 
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enhanced GCN1 association with polysomes by ATP (23, 24).  Since mammals contain three ABCF 
family members, compared to two family members in yeast, it is possible that another mammalian ABCF 
family member or other protein compensates for lost ABCF3 function (45-47).  However, ABCF3 is the 
only mammalian ABCF family member with an N-terminus similar to yeast GCN20 and C. elegans 
ABCF3, suggesting mammalian ABCF3 is a GCN20 ortholog.  Further experiments will be required to 
understand the function of ABCF3, if any, in amino acid sensing in mammalian cells. 
 
Functions and Mechanisms of the GCN2-independent GCN1 branch 
GCN1 mediates several GCN2-independent therapeutic transcriptional effects of HF, but whether GCN1 
mediates additional GCN2-independent functions or acts outside the inflammatory context is unknown.  
GCN1 has not been functionally studied in mammalian cells, and its localization within the cell has not 
been analyzed, but several observations suggest GCN1 may be present in the nucleus.  Although GCN1 is 
assumed to be cytoplasmic, due to its ascribed translational function in yeast, in both yeast and mammals 
GCN1 putatively interacts with a large number of nuclear proteins, suggesting either that GCN1 is present 
in the nucleus or might interact with a subset of nuclear proteins that are retained in the cytoplasm (31-
40).  In addition, this chapter shows that GCN1 is required for GCN2-independent transcriptional 
changes, also raising the possibility of GCN1 function in the nucleus.  We show that HF treatment shifts 
GCN1 from a digitonin resistant fraction (consistent with organelle association) into a digitonin released 
cytoplasmic fraction, suggesting that GCN1 association with distinct fractions is dynamically regulated 
by HF. Immunofluorescence analysis was unable to resolve where this shift corresponded to within the 
cell, and did not identify a clear nuclear GCN1 fraction.  It is possible GCN1 is not present in the nucleus, 
but this cannot be definitively concluded from the data shown.  A small portion of GCN1 could be present 
in the nucleus below the detectable threshold of our method, or a portion of GCN1 may move into the 
nucleus under conditions not tested here. Several observations support GCN1 presence in the nucleus, in 
addition to putative nuclear GCN1 interactors.  GCN2 has recently been reported to be present in nucleoli 
in several mammalian cell lines with nucleolar levels increasing upon amino acid starvation (48).  Since 
GCN2 phosphorylation upon uncharged tRNA accumulation requires GCN1 association, GCN1 may 
likewise be present in nucleoli.  Recent studies have also reported protein translation in the nucleus, and 
GCN1 as a translational component, could be associated with ribosomal components in the nucleus (49).  
In addition, tRNAs accumulate in the nucleus upon nutrient deprivation, which could plausibly play 
regulatory roles by activating nuclear GCN2 and GCN1 (50).   
 
Further experiments are required to confirm GCN1 nuclear interactors   
GCN1 is a large, scaffold-like protein whose amino acid sequence contains numerous protein-protein 
interaction elements, including LxxLL motifs and HEAT domains, which in other proteins are known to   
interact with nuclear proteins (51).   Several studies have identified GCN1 as an interactor with a large 
number of nuclear regulators, including transcription factors e.g. SREBP, components of the splicing 
apparatus e.g. CDC5L, components of the transcriptional machinery: components of the mediator 
complex, and several nuclear receptors (31-40).  My own studies, however, have failed to reproduce 
several previously identified interactions (not shown). Our analysis of GCN1 interactors from nuclear-
associated lysate indicated little overlap with previously identified interactors, although follow-up 
experiments revealed commercial GCN1 antibody was not sufficiently specific to reliably identify GCN1 
co-precipitating proteins. The limitations of the commercial antibody shown here demonstrate that an 
alternative approach will be required to identify GCN1 protein interactors.  
 
A branch point exists in the mammalian AAR and GCN1 mediates key GCN2-independent therapeutic 
transcriptional changes upon HF treatment, but how these effects are mediated remains unclear. In the 
next chapter we return to the system and conditions in which we know the GCN2-independent GCN1 
branch mediates effects and characterize a full transcriptional program mediated by this new branch in the 
presence and absence of inflammatory stimulation.  In addition, learning from the experiments in this 
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chapter, we set up an improved system to pull down GCN1 to identify potential pathway mediators that 
regulate the identified transcriptional changes. 
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METHODS 
 
Reagents 
HF and HFol (Prepared by Dr. R.Mazitschek, MGH) 
TNFα (Sigma) 
Effectene (Qiagen) was used for transient transfections. 
ANTIBODIES:  GCN1 (Novus NB100-97851: used for all westerns and IPs unless otherwise indicated, 
Sigma HPA 019648), pGCN2 (Abcam/Epitomics EPR2320Y /AB75836), GCN2 (CST 3302S), peIF2α 
(3398S), eIF2α (CST 9722), ABCF3 (Novus NBP1-84781: used for all westerns unless otherwise 
indicated, Bethyl A302-496A-T), Actin (Sigma A5441), NFkB1 (CST 13586S and 3035S), Zeb1 (Bethyl 
A301-922A-T), c-Myc (CST 5605, CREB (CST 9197, PARP (CST 9532S), H3 (CST 3638S), S6 (CST 
2317), GAPDH (Genetex GTX627408), ERP29 (Genetex GTX102225), GCN1 sera (generated against 
GCN1 epitope: QFFVPDALNDRHPDVRKC, Abfrontiers) 
 
Cell Lines and Cell Culture 
HCT116 (ATCC), K4 (Dr Evelyn Murphy (University College Dublin)), HeLa (ATCC), and 293T 
(ATCC) were cultured at 5% CO2 at 37°C in DMEM supplemented with 10% FBS, L-glutamine, and 
antibiotics (K4 and HCT116 cells were further supplemented with sodium pyruvate).  
 
For TNFα-stimulated experiments, cells were shifted into K4 cell media with 0.2% FBS instead of 10% 
FBS 24 hours before the HFol treatment.  HFol or carrier alone (DMF) were added directly to cells 
without media change.  After 16 hours, 10 ng/mL TNFα (Sigma) was added directly to cells.  After 8 
hours, RNA was extracted for analysis.  
 
cDNAs   
The following cDNAs were used:  pCSX, pCSX-eGFP, pCSX-3Flag-hGCN1 (N-terminally tagged), 
tdTomato-C1-hGCN1 (N-terminally tagged) (hGCN1 from pCSX-3Flag-hGCN1 cloned into tdTomato 
using XbaI and EcoRI), pCSX-3Flag-shResistant-hGCN1 (N-terminally tagged) (shRNA GCN1 target 
sequence codons were changed to wobble codons to encode same GCN1 amino acid sequence but to 
make nucleotide sequence different from target sequence of shRNA.  shRNA target sequence mutated to 
ACACAGGCTTACAGGTAATAA using gBlock sequence (IDT) provided below to replace portion of 
GCN1 in pCSX-3Flag-GCN1 with BstEII and BclII.), pEV-p105-WT (Addgene 23952) NFkB1, pCSX-
3Flag-hZeb1 (hZeb1 cDNA cloned from pCR-Blunt II-TOPO MGC human Zeb1 sequence-verified 
cDNA, clone ID: 40036600 (Dharmacon)). 
 
gBlock sequence: 
ACTTGGGTCACCTGAAATCCAACAGTCCCCGCCTGATGGATGAAGCTGTGCTGGCACTGCGG
AACCTGGCACGCCAGTGCAGTGACTCTTCGGCCATGGAATCCCTGACCAAGCACCTATTTGC
TATCCTCGGAGGCTCGGAAGGAAAACTAACTGTTGTAGCCCAGAAGATGAGCGTCCTCTCAG
GGATTGGGAGCGTCAGTCATCACGTGGTGTCTGGACCTTCCAGTCAGGTCCTGAATGGGATC
GTGGCTGAGCTGTTCATCCCGTTCCTTCAGCAGGAAGTTCATGAAGGGACCTTGGTACACGC
TGTCTCAGTCCTGGCTCTCTGGTGTAACCGATTCACTATGGAAGTGCCCAAGAAGCTCACTG
AATGGTTCAAAAAAGCTTTCAGCCTTAAAACCTCCACATCTGCGGTGAGGCATGCCTACCTG
CAGTGCATGTTGGCCTCTTACCGGGGTGACACGCTGTTGCAGGCCCTGGACTTACTGCCCTT
GCTCATCCAGACAGTGGAGAAGGCAGCCTCCCAAAGCACTCAGGTTCCCACCATCACCGAA
GGGGTTGCCGCAGCCTTGTTGCTCTTAAAGTTGTCAGTGGCTGACTCACAGGCTGAGGCCAA
ACTGAGCAGTTTCTGGCAGTTGATTGTGGATGAGAAAAAGCAGGTTTTCACTTCTGAGAAAT
TCCTGGTCATGGCTTCAGAGGATGCCCTGTGTACTGTGTTGCATCTGACAGAGAGACTTTTCC
TTGACCACCCACACAGGCTTACAGGTAATAAAGTTCAGCAGTACCACCGGGCTCTGGTGGCG
GTGCTCCTGAGCCGCACCTGGCACGTCCGCAGGCAGGCTCAGCAGACAGTTCGGAAGCTGCT
GTCCTCTCTTGGGGGCTTTAAGCTGGCGCACGGACTCTTGGAGGAGCTGAAGACTGTCCTCA
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GTTCTCACAAGGTGCTGCCCTTAGAGGCTTTGGTGACTGATGCTGGAGAGGTGACTGAGGCA
GGCAAGGCCTACGTGCCTCCACGGGTCCTGCAGGAGGCTCTGTGTGTCATCTCCGGTGTGCC
AGGGCTCAAGGGTGATGTCACCGACACTGAACAACTGGCCCAGGAAATGCTGATCAAAGTC  
 
CRISPR-mediated knockout HCT116 cells 
HCT116 ABCF3 knockout cells were generated using the Origene knockout kit according to the 
manufacturer’s protocol (Catalogue #: KN201403: contains gRNA containing plasmids KN201403G1 
and KN201403G2, and donor cassette containing plasmid KN20143D)  Clonal lines were isolated using 
cloning rings (Sigma).  For genomic PCR confirmation, DNA was extracted using DNeasy Blood and 
Tissue Kit (Qiagen).  PCR was performed using ChoiceTaq Polymerase (Denville Scientific) according to 
manufacturer’s protocol.  To prevent contamination, dTTP was replaced with dUTP, and 1 unit Uracil-
DNA Glycosylase (UNG) was added to PCR reactions, and incubated at RT for 10 minutes prior to PCR. 
 
ABCF3 Guide RNA Target Sequences: 
G#1: GCCGATTCAGTTCTGCTTAC, G#2: CAGAACTGAATCGGCCGGCT,  
gSc: GCACTACCAGAGCTAACTCA 
Genomic PCR Primer Sequences: 
For left side homology template:  lha42f : TGCAAGGAAGGGCGAGATTT,  
template242r: CTCGTCGCTCTCCATGCTAG 
For right side homology template:  template2657F: ATCAGCAGCCTCTGTTCCAC,  
rha3037R: GTTCCCCTACAGCTTCCACC 
For genome:  genome42F: TGCAAGGAAGGGCGAGATTT,  
genome498R: GTTCCCCTACAGCTTCCACC 
 
GCN1 and GCN2 CRISPR-mediated knockout HCT116 cell lines were generated and obtained from 
Changqian Zhao. 
 
shRNA-mediated knockdown GCN1 and GCN2 HeLa and K4 by lentiviral infection 
Virus was produced by co-transfecting the transfer vector, pLKO.1 containing the shRNA inserts given 
below, with the envelope plasmid pMD2.G, and packaging plasmid psPAX2, into 293T cells plated on 
poly-D-lysine coated plates at a ratio of 2:1:1.5, respectively.  Media was changed 24 hours after 
transfection and the virus-containing supernatant was collected 72 hours after transfection and passed 
through a 0.45 µm filter to eliminate cells.  Target HeLa or K4 cells in 6-well tissue culture plates were 
infected in media containing 5 µg/mL of polybrene.  Media was changed after 6 hours.  After 16 hours 
infection was repeated.  After 24 hours, cells were selected with puromycin.  After selection, cells were 
maintained in respective cell media with 0.25 ug/mL puromycin.   
 
pLKO.1 shGCN1: HsSH00265698 (Dana Farber/Harvard Cancer Center DNA Resource Core)  
CCGGGCATAGACTCACTGGCAACAACTCGAGTTGTTGCCAGTGAGTCTATGCTTTTT (target 
sequence in bold) 
pLKO.1 shGCN2: HsSH00114723 (Dana Farber/Harvard Cancer Center DNA Resource Core)  
CCGGGCCTAACTGGTGAAGAAGTATCTCGAGATACTTCTTCACCAGTTAGGCTTTTTG 
(target sequence in bold) 
pLKO.1 shScrambled:  1864 (Addgene) 
CCTAAGGTTAAGTCGCCCTCGCTCGAGCGAGGGCGACTTAACCTTAGG  
 
shRNA-mediated scrambled, GCN1, and GCN2 knockdown K4 cells were generated and obtained from 
Yeon-Jin Kim. 
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Cell Fractionations 
KIT:  HeLa and K4 cells were fractionated with the Thermo Subcellular Protein Fractionation Kit for 
Cultured Cells (78840) according to the manufacturer’s protocol with the following modifications.  Cells 
were fractionated from 10 cm tissue culture plates and reagent volumes were based on a packed cell 
volume of 50 uL.  After cytoplasmic extractions (step 2) and membrane extractions (step 5), pellets were 
washed twice with PBS followed by 2 minute 500G spins, or twice with MEB followed by 3000 G spins, 
respectively.  In step 10, the extraction was incubated for 10 min at 37C and briefly vortexed after 5 
minutes. 
 
DIGITONIN SEQUENTIAL EXTRACTION: Cells were sequentially permeabilized with digitonin 
buffer (110 mM KOAc, 25 mM KHEPES pH 7.2, 2.5 mM MgCl, 1 mM EGTA, 0.015% digitonin) for 5 
minutes, washed with wash buffer D (110 mM KOAc, 25 mM KHEPES pH 7.2, 2.5 mM MgCl, 1 mM 
EGTA, 0.004% digitonin) for 1 minute, lysed with NP-40 buffer (110 mM KOAc, 25 mM KHEPES pH 
7.2, 2.5 mM MgCl, 1% NP-40) for 5 minutes, washed with wash buffer N (110 mM KOAc, 25 mM 
KHEPES, pH 7.2, 2.5 mM MgCl2, 1% NP-40) for 1 minute, and lysed with High Salt buffer (400 mM 
KOAc, 25 mM KHEPES, pH 7.2, 15 mM MgCl2, 1% NP-40), washed with wash buffer H (400 mM 
KOAc, 25 mM KHEPES, pH 7.2, 15 mM MgCl2, 1% NP-40), and lysed with RIPA.  Protease and 
phosphatase inhibitors were also added to all lysis buffers.  In figure 3 the following modifications were 
performed: cells were scraped into and lysed in microcentrifuge tubes rather then lysed directly on the 
plate and spun between subsequent extractions, and the NP-40/high salt extraction was performed 
together and incubated for 30 minutes rather than 5 minutes.   
 
HYPOTONIC/HIGH SALT DIGNAM LYSIS:  Based on Folco et al. 2012 (52).  Cells were resuspended 
in hypotonic buffer (10mM HEPES, pH 7.9, 1.5mM MgCl2, 10mM KCl, 0.2mM PMSF, 0.5mM DTT) 
and spun.  The pellet was resuspended in 3 volumes hyptonic buffer and incubated for 10 minutes on ice.  
Cells were briefly homogenized with a mini-dounce and spun.  The supernatant was saved as the 
hypotonic fraction.  The pellet was further extracted in high salt buffer (20mM HEPES, pH 7.9, 1.5mM 
MgCl2, 0.8 M KCl, 0.2mM EDTA, 25% Glycerol, 0.2mM PMSF, 0.5mM DTT) according to the 
reference, and spun.  The supernatant was saved as the high salt fraction. 
 
Protein Extraction, SDS PAGE, and Immunoblotting 
Protein content was quantified with the Pierce BCA protein assay kit (Thermo Scientific) except for cell 
fractionations.  Protein samples were diluted in 3X Laemmli buffer (160 mM Tris pH 6.8, 6% SDS, 20% 
glycerol, 0.01% bromophenol blue, 0.04% β-Mercaptoethanol), boiled for 5 minutes, and electrophoresed 
through pre-cast Bolt 4-12 % Bis-Tris Plus gels (Invitrogen).  The amount of total protein loaded per well 
was standardized across each experiment except for cell fractionation experiments. Proteins were 
transferred to nitrocellulose membrane (GE Healthcare), blocked with 5% milk and blotted with 
appropriate antibodies overnight at 4°C. Blot were imaged with the Syngene PXi imager.  
 
RNA Extraction and Quantitative Real-Time PCR  
Cells were extracted with 1 mL TRIZOL (Ambion) and RNA purified with the Direct-Zol RNA MiniPrep 
kit (Zymo Research).  RNA yield and purity were quantified using an ND-1000 spectrophotometer and 
cDNA was synthesized using the ABI High Capacity cDNA Reverse Transcription Kit (Ambion). Primer 
pairs were designed using Universal ProbeLibrary Assay Design Center (https://qpcr.probefinder.com).  
The following primer pairs and probes were used: TRIB3 (TCCAGATCGTGCAACTGCT, 
CTTCCTGGACGGGGTACA, #16), GAPDH (AGCCACATCGCTCAGACAC, 
GCCCAATACGACCAAATCC, #60), ASNS (GATGAACTTACGCAGGGTTACA, 
CGCGGAGAACATCAAACAA, #63), ATF3 (TTTGCCATCCAGAACAAGC, 
CATCTTCTTCAGGGGCTACCT, #53) CXCL10 (GAAAGCAGTTAGCAAGGAAAGGT, 
GACATATACTCCATGTAGGGAAGTGA, #34), MMP13 (CCAGTCTCCGAGGAGAAACA, 
AAAAACAGCTCCGCATCAAC, #73), IDO1 (GTGTTTCACCAAATCCACGAT, 
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CTGATAGCTGGGGGTTGC, #20).  Quantitative real-time PCR was performed using the LightCycler 
480 ProbesMaster and UPR Light Cycler System (Roche).  Relative gene expression changes were 
measured using the comparative CT method, X=2-ΔΔCT.  Target gene expression was normalized with 
GAPDH as the respective endogenous control.  
 
Immunofluorescence and Microscopy 
Cells were plated on sterilized coverslips (#1.5 12 mm round, Warner CS-12R17) in 24-well dishes.  
Cells were washed once with PBS and fixed with 500 uL 2% paraformaldehyde in 1X PBS for 30 
minutes.  Fixed cells were washed twice with 500 uL PBS for 5 minutes.  Cells were permeabilized with 
0.25% Triton-X-100 in 10% NGS, 1X PBS for 30 minutes.  Cells were incubated overnight at 4°C with 
primary antibody diluted in 0.1% Triton in 10% NGS, 1X PBS at 1:20 or 1:50.  Cells were washed 3 
times with PN buffer (1% NGS, 1X PBS), 1X with 1M LiCl, and 2X with PN buffer for 5 minutes each.  
Cells were then incubated in anti-rabbit Alexa488 conjugated secondary antibody (CST) diluted at 1:500 
in 0.1% Triton-x-100 in 10% NGS, 1X PBS for 1 hour.  Cells were further washed 1X with 0.1% Triton-
x-100 PN for 5 minutes, incubated 10 minutes with 0.5 ug/mL Hoeschst 33258 to stain nuclei, followed 
by 2X 0.1% Triton-x-100 PN for 10 minutes each, and 3X with PN for 10 minutes each.  All steps were 
performed at room temperature unless indicated otherwise.  Cover slips were mounted cell side down and 
imaged with a Yokogawa CSU-X1 spinning disk confocal on a Nikon Ti fluorescence microscope with 
the 100X oil Plan Apo λ N.A. 1.45 Type: DIC N2 objective, at the Nikon Imaging Center, Harvard 
Medical School.  Images were analyzed using ImageJ.   
 
IP-MS 
HeLa nuclear extracts for the IP-MS were prepared and immuno-precipitated by Binkai Chi in the Robin 
Reed lab, Harvard Medical School.  Nuclear lysates were prepared according to Folco et al. 2012 (52).  
Novus GCN1 antibody (NB100-97851) was crosslinked to Protein A beads in a ratio of 2:1 
antibody:beads with dimethyl pimelimidate.  Prior to immunoprecipitation 75 uL of HeLa nuclear lysate 
was incubated at 30C for 20 min with 75 uL SDB (20 mM HEPES pH 7.9, 100 mM KCl ), 10 uL 12.5 
mM ATP, 10 uL 80 mM MgCl2, 10 uL 0.5M creatine phosphate, and 70 uL water.  After incubation, mix 
was spun at 14,000 rpm at 4°C.  15 uL was taken as an input control sample.  125 uL IP buffer (1x PBS, 
0.1% Triton-X100, 0.6 mM PMSF, 2x 25X Roche Complete Mini, EDTA-free protease inhibitor) was 
added to remaining mix, combined with 20 uL GCN1-crosslinked protein A beads, and incubated at 4°C 
for 4h or overnight.  Beads were washed 6x with 0.1% Triton-X-100, 0.2 mM PMSF, 1x with PBS, and 
eluted with 60 uL PGB (138 mM Tris, 4.5% SDS, 22% glycerol, bromophenol blue) for 20 min at room 
temperature.  Eluate was TCA precipitated and sent for LC/MS/MS analysis at the Taplin Mass 
Spectrometry Facility, Harvard Medical School.  Identified proteins were compared to two control IP-MS 
sample sets from the Reed lab (matrin IP and IgG IP). 
 
Follow-up NFkB1 and Zeb1 IPs 
Confirmation of NFkB1 and Zeb1 co-immunoprecipitation with Novus GCN1 antibody was performed as 
above with the following modifications: GCN1 antibody was coupled rather then crosslinked to protein A 
beads for 1 hour at room temperature, eluate was analyzed by immunoblot, and immunoprecipitation with 
equivalent amount of IgG was used as control IP. 
  
Follow up coIPs in Figure 7b were immunoprecipitated with respective antibodies or IgG from HeLa cells 
lysed with 1% triton (20 mM Tris-HCl (pH 7.5), 150 mM NaCl, 1 mM EDTA, 1 mM EGTA, 1% triton + 
protease inhibitors (Complete and PMSF).  Lysate was incubated with primary antibody at recommended 
concentrations overnight at 4C.  Protein A beads were added and incubated for an additional 4 hours, 
washed 6x with lysis buffer, eluted in Laemmli buffer and analyzed by immunoblot.  For GCN1 sera IP 
the following modification were made.  Sera was coupled to beads at a 5:1 ratio of sera:beads for 1 hour 
at room temperature.  A fraction of coupled beads were incubated with GCN1 sera peptide as control.  
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Sera coupled beads and peptide blocked sera coupled beads were then incubated with cell lysate 
overnight.  
 
Statistics 
Data were analyzed using GraphPad PRISM, version 6.    
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FIGURES AND TABLES 
 
Fig 1 | GCN1, but not ABCF3 is required for phosphorylation of GCN2 by the AAR in mammalian 
cells.  (a)  GCN1, GCN2, and ABCF3 knockout HCT116 cell lines were treated with 25 or 100 nM HF 
for 30 minutes and assayed by immunoblot for phospho-GCN2 and phospho-eIF2α.  Total GCN1, 
ABCF3, GCN2, eIF2α, and actin are shown as loading controls and to demonstrate successful knockout 
in respective knockout cell line. (b)  mRNA expression of characteristic AAR induced genes from GCN1, 
GCN2, and ABCF3 knockout HCT116 cell lines treated with 50 or 200 nM HF for 8 hours.  mRNA 
expression was normalized to expression of GAPDH mRNA and is represented as the mean of biological 
triplicates ± s.d.  GCN2-/- and GCN1-/- HCT116 data in (a) are representative of a single experiment but 
mirror observations observed by shRNA-mediated knockdown of GCN2 and GCN1 in multiple cell types 
(not shown).  ABCF3-/- HCT116 data in (a) are representative of 3 separate experiments.  Data in (b) are 
representative of a single experiment but mirror observations observed by shRNA-mediated knockdown 
of GCN2, GCN1, and ABCF3 in K4 cells (not shown, Kim et al, manuscript in preparation). 
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Fig 2 | Several key HF therapeutic effects require GCN1 but not GCN2.  (a) mRNA expression of 
TRIB3 (characteristic AAR pathway induced gene) and CXCL10 and MMP13 (proinflammatory genes) 
in shRNA-mediated knockdown control (shScrambled), GCN1 (shGCN1), and GCN2 (shGCN2) K4 cells 
treated with 250 nM Hfol for 24 hours and 10 ng/mL TNFα for 8 hours. (b)  Comparison of GCN2 
phosphorylation by immunoblot of wildtype K4 treated with HF or HFol at indicated concentrations for 
30 minutes.  (c)  Comparison of CXCL10 and IDO1 mRNA expression (proinflammatory genes) with HF 
or Hfol treatment  at indicated concentrations and TNFα treatment in shRNA-mediated knockdown K4s 
as described in (a).  Data in (a) and (c) are representative of 6 independent experiments.  Data in (b) is 
representative of 1 experiment but has been repeated in other cell types.   
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Fig 3 | Several different biochemical fractionation methods consistently show presence of GCN1 in 
cell fractions that contain nuclear components.  (a)  Fractionation of HeLa and K4 cells using the 
Thermo Subcellular Protein Fractionation Kit for Cultured Cells and analysis by immunoblot shows a 
significant amount of GCN1 is present in the nuclear-associated fractions.  GAPDH, S6, PARP, H3, and 
actin are present in specific fractions as expected.  (b)  Digitonin sequential extraction and Dignam 
extraction compared in HeLa and K4 cells.  Digitonin sequential extraction consisted of an initial 
extraction using digitonin, to selectively extract the cytoplasm, followed by extraction of the remaining 
pellet with NP-40 and high salt.  Dignam extraction consisted of hypotonic lysis followed by high salt 
extraction of the remaining pellet. HeLa data in (a) is representative of 2 separate experiments, while K4 
data is representative of a single experiment.  Similar results were obtained in both cell lines using 
additional commercial extraction kits (data not shown).  Data in (b) are representative of at least 3 
separate experiments. 
 
 
 
Fig 4 | HF treatment shifts GCN1 localization between cellular fractions.  Sequential digitonin 
extraction of K4 cells treated with 250 nM HF for 30 minutes.  Cells were sequentially extracted on 10 
cm plates first by digitonin, then NP-40, then high salt, and finally all remaining material was extracted 
with RIPA.  Data are representative of at least 3 independent experiments. 
 
KEY:			
C	=	cytoplasmic	
M	=	membrane	
N	=	nuclear	(soluble)	
Nc	=	nuclear	(chroma5n	
bound)	
P	=	pellet	(cytoskeleton)	
	Fig	3	|	Several	diﬀerent	biochemical	frac?ona?on	methods	consistently	show	presence	of	GCN1	in	cell	frac?ons	that	contain	nuclear	components.		(a)		Frac5ona5on	of	
HeLa	and	K4	cells	using	the	Thermo	Subcellular	Protein	Frac5ona5on	Kit	for	Cultured	Cells	and	analysis	by	immunoblot	shows	a	signiﬁcant	amount	of	GCN1	is	present	in	the	
nuclear-associated	frac5ons.		GAPDH,	S6,	PARP,	H3,	and	ac5n	are	present	in	speciﬁc	frac5ons	as	expected.		(b)		Digitonin	Sequen5al	extrac5on	and	Dignam	extrac5on	
compared	in	HeLa	and	K4	cells.		Digitonin	sequen5al	extrac5on	consisted	of	a	ﬁrst	extrac5on	using	digitonin,	to	selec5vely	extract	the	cytoplasm,	followed	by	extrac5on	of	
the	remaining	pellet	with	NP-40	and	high	salt.		Dignam	extrac5on	consisted	of	hypotonic	lysis	followed	by	high	salt	extrac5on	of	the	remaining	pellet.	(a)	is	representa5ve	of	
one	experiment	but	data	consistent	with	results	of	other	commercial	kits.		(b)	is	representa5ve	of	over	3	independent	experiments	with	similar	condi5ons.			
(a)	Pierce	Commercial	Extrac?on	kit:	
	
(b)	Digitonin	Sequen?al	Extrac?on	and	Dignam	Extrac?on:	
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Fig	4	|	HF	treatment	shiQs	GCN1	localiza?on	between	cellular	frac?ons.		Sequen5al	digitonin	extrac5on	of	K4	cells	treated	with	250	nM	
HF	for	30	minu s.		Cells	were	sequen5ally	extracted	on	10	cm	plates	ﬁrst	by	digitonin,	then	NP-40,	then	high	salt,	and	ﬁnally	all	remaining	
material	was	extracted	with	RIPA.		Representa5ve	of	at	least	3	independent	experiments.	
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Fig 5 | GCN1 localizes to cytoplasm in multiple mammalian cells.  (a)  Images of HeLa, shRNA-
mediated GCN1 knockdown HeLa, and K4 cells stained with commercial Novus GCN1 antibody with 
and without digitonin permeabilization.  (b) Same cells as (a) stained with commercial Sigma GCN1 
antibody with and without digitonin permeabilization.  (c) Images of wildtype and GCN1 knockout 
HCT116 cells stained with Novus or Sigma GCN1 antibodies. Third row is identical sample as second 
row with adjusted contrast to avoid saturation.  For all images antibody concentrations are indicated and 
IgG stained samples are provided as controls.  Data in (a) and (b) are representative of at least 3 separate 
experiments.  Data in (c) are representative of a single experiment.   
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Fig 6 | Shift in GCN1 localization by HF treatment is not observed by immunofluorescence.  (top) 
Images of HeLa stained with Novus and Sigma GCN1 antibodies with and without treatment with 800 
nM HF for 30 minutes.  (bottom) Images of K4 stained with Sigma GCN1 antibody with and without 
treatment with 400 nM HF for 3 hours. For all images antibody concentrations are indicated and IgG 
stained samples are provided as controls.  Data are representative of at least 2 separate experiments.   
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Table 1 | Nuclear isolation of GCN1 from HeLa cells revealed putative interactors but also non-
specificity of commercial antibody. GCN1 was immunoprecipitated from HeLa nuclear extract with 
commercial antibody (Novus), eluted, and analyzed by mass spectrometry to identify nuclear GCN1 
interactors.  Table shows 18 most abundant proteins found in the eluate.   
 
 
 
 
 
Table	1	|	Nuclear	Isola0on	of	GCN1	from	HeLa	cells	Revealed	Puta0ve	interactors	but	also	non-speciﬁcity	of	Commercial	An0body.	GCN1	was	
immunoprecipitated	from	HeLa	nuclear	extract	with	commercial	an:body	(Novus),	eluted,	and	analyzed	by	mass	spectrometry	to	iden:fy	
nuclear	GCN1	interactors.		Table	shows	18	most	abundant	proteins	in	the	eluate.			
Unique:	 Total:	 reference:	 Gene	Symbol:	 MW	(kDa):	
189	 421	 Q92616_GCN1L_HUMAN	 GCN1L1	 292.57	
24	 25	 P37275_ZEB1_HUMAN	 ZEB1	 124	
22	 22	 Q9ULJ3_ZBT21_HUMAN	 ZBTB21		 118.8	
20	 20	 P19838_NFKB1_HUMAN	 NFKB1	 105.29	
18	 19	 Q7Z6Z7_HUWE1_HUMAN	 HUWE1	 481.59	
9	 11	 Q96SU4_OSBL9_HUMAN	 OSBPL9			 83.13	
9	 9	 Q14202_ZMYM3_HUMAN	 ZMYM3		 152.28	
8	 9	 P34931_HS71L_HUMAN	 HSPA1L	 70.33	
8	 9	 O15523_DDX3Y_HUMAN	 DDX3Y	 73.11	
8	 8	 Q92734_TFG_HUMAN	 TFG	 43.42	
8	 8	 O75145_LIPA3_HUMAN	 PPFIA3		 133.41	
7	 7	 P56545_CTBP2_HUMAN	 CTBP2	 48.91	
7	 7	 Q13363_CTBP1_HUMAN	 CTBP1	 47.51	
6	 6	 P20936_RASA1_HUMAN	 RASA1	 116.33	
6	 6	 P54652_HSP72_HUMAN	 HSPA2	 69.98	
6	 6	 P00338_LDHA_HUMAN	 LDHA	 36.67	
5	 5	 P17980_PRS6A_HUMAN	 PSMC3	 49.17	
5	 5	 Q8NFZ5_TNIP2_HUMAN	 TNIP2	 48.67	
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Fig 7 | Follow up experiments indicate commercial GCN1 antibody has non-specific target 
recognition.  (a)  IP-MS NFkB1 and Zeb1 results are repeatable when HeLa high salt lysate is immuno-
precipitated with commercial GCN1 antibody (Novus). Arrows indicate p50 and p105 forms of NFkB1, 
and Zeb1 band.  Data is representative of two separate experiments.  (b) Antibody pull downs of GCN1 
and NFkB1 from HeLa 1% triton lysates. (top panel) Commercial GCN1 (Novus) antibody co-
precipitates NFkB1, but NFkB1 pull down does not co-precipitate GCN1.  (bottom panel) GCN1 sera 
recognizing a distinct epitope from the commercial GCN1 (Novus) antibody does not co-precipitate 
NFkB1.  A second NFkB1 antibody recognizing a different epitope from the antibody used in top panel 
does not co-precipitate GCN1. (c) Immunoblot of HeLa high salt extract with ectopically expressed 
GCN1 or Zeb1 shows that commercial GCN1 antibody (Novus) recognizes a ZEB1 transfection 
dependent band at exact size of Zeb1. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig	7	|	Follow	up	experiments	indicate	commercial	GCN1	an:body	has	non-speciﬁc	target	recogni:on.		(a)		IP-MS	NFkB1	and	Zeb1	results	are	
repeatable	when	HeLa	high	salt	lysate	is	immunoprecipitated	with	commercial	GCN1	anDbody	(Novus).	Arrows	indicate	p50	and	p105	forms	of	
NFkB1,	and	Zeb1	band.		(b)	AnDbody	pull	downs	of	GCN1	and	NFkB1	from	HeLa	XXXX	extracts.	(top	panel)	Commercial	GCN1	(Novus)	anDbody	
coprecipitates	NFkB1,	but	NFkB1	pull	down	does	not	coprecipitate	GCN1.		(boPom	panel)	GCN1	sera	recognizing	a	disDnct	epitope	from	the	
commercial	GCN1	(Novus)	anDbody	does	not	co-precipitate	NFkB1.		A	second	NFkB1	anDbody	recognizing	a	diﬀerent	epitope	from	the	anDbody	
used	in	top	panel	does	not	co-precipitate	GCN1.			(c)	Immunoblot	of	HeLa	high	salt	extract	with	ectopically	expressed	GCN1	or	Zeb1	shows	that	
commercial	GCN1	anDbody	(Novus)	recognizes	a	ZEB1	transfecDon	dependent	band	at	exact	size	of	Zeb1.	
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SUPPLEMENTARY FIGURES 
 
 
 
 
Fig S1 | Confirmation of ABCF3 knockout HCT116 cells.  (a)  Comparison of ABCF3 protein levels 
with two different commercial antibodies and AAR pathway activation by HF treatment by immunoblot 
analysis.  (b)  Genomic PCR confirmation of ABCF3 knockout clonal lines.  Gel showing PCR fragments 
resulting from PCR reactions using primers described by diagram on right. The lower panel is a shorter 
exposure.  G1-3, 4, 5 are ABCF3 knockout clonal lines and gSc-1, 2 are control scrambled knockout 
clonal lines.   
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Fig	S1	|	Conﬁrma/on	of	ABCF3	knockout	HCT116	cells.		(a)		Comparison	of	ABCF3	protein	levels	with	two	diﬀerent	commercial	an5bodies	and	
AAR	pathway	ac5va5on	by	HF	treatment	by	immunoblot.		(b)		Genomic	PCR	conﬁrma5on	of	ABCF3	knockout	clonal	lines.		Gel	showing	PCR	
fragments	described	by	diagram	on	right.	The	lower	panel	is	a	shorter	exposure.		G1-3,	4,	5	are	ABCF3	knockout	clonal	lines	and	gSc-1,	2	are	
control	scrambled	knockout	clonal	lines.			
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Fig S2 | GCN1 is required for GCN2 activation in HeLa. shRNA-mediated scrambled and GCN1 
knockdown cells were transfected with empty vector or shRNA-resistant GCN1 for 24 hours and then 
treated with indicated concentrations of HF for 1 hour.  Lysates were assayed by immunoblot for 
phospho-GCN2 and phospho-eIF2α.  Total GCN1 demonstrates efficient knockdown of GCN1 levels by 
shRNA and actin is shown as a loading control.  Data are representative of a single experiment. 
 
 
 
 
 
 
Fig S3 | Distribution of ectopically expressed tagged GCN1 by immunoblot and fluorescence 
microscopy.  (a) Comparison of commercial GCN1 antibodies and comparison of tagged ectopically 
expressed GCN1 in digitonin sequential extractions by immunoblot in HeLa.  c-Myc, erp29, eIF2α, and 
actin are provided as markers for cell fractions and as loading controls. (b)  (top panel) Live-cell images 
of td-Tomato-GCN1 fluorescence in td-Tomato-GCN1 transfected HeLa.  (bottom panel) Images of td-
Tomato-GCN1 fluorescence in fixed td-Tomato-GCN1 transfected K4.  Data are representative of a 
single experiment. 
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Fig	S2	|	GCN1	is	required	for	GCN2	ac/va/on	in	HeLa.	shRNA-mediated	scrambled	and	GCN1	knockdown	cells	were	transfected	with	empty	
vector	or	shRNA-resistant	GCN1	for	24	hours	and	then	treated	with	indicated	concentra5ons	of	HF	for	1	hour.		Lysates	were	assayed	by	
immunoblot	for	phospho-GCN2	and	phospho-eIF2a.		Total	GCN1	demonstrates	eﬃcient	knockdown	of	GCN1	levels	by	shRNA	and	ac5n	is	shown	
as	a	loading	control.	
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Fig	S3	|	Distribu/on	of	ectopically	expressed	tagged	GCN1	by	immunoblot	and	ﬂuorescence	microscopy.		(a)	Comparison	of	commercial	GCN1	
an5bodies	and	comparison	of	tagged	ectopically	expressed	GCN1	in	digitonin	sequen5al	extrac5ons	by	immunoblot	in	HeLa.		C-Myc,	erp29,	
eIF2α,	and	ac5n	are	provided	as	markers	for	cell	frac5ons	and	loading	controls.	(b)		Live	cell	images	of	td-Tomato-GCN1	ﬂuorescence	in	td-
Tomato-GCN1	transfected	HeLa.		(bofom	panel)	Images	of	td-Tomato-GCN1	ﬂuorescence	in	ﬁxed	td-Tomato-GCN1	transfected	K4.			
Key:	
-					=	Control	GFP	transfected	
T				=	tdTomato-GCN1	transfected	
F				=	3Flag-GCN1	transfected	
ac5n	
NP-40/HS	 RIPA	
Novus	
GCN1	
Sigma	
GCN1	
Flag	
c-Myc	
erp29	
		-			-			T			F		F			-			-			T			F			F		-			-			T			F		F	
DIG	
eIF2α	
GCN1	
HeLa	
(a)	
Live	cell	imaging	(confocal)	in	HeLa	transfected		
with	tdTomato-GCN1	
(b)	
Fixed	K4	transfected	with	tdTomato-GCN1	
77 
REFERENCES 
 
1. Grohmann U, et al. (2017) Amino-acid sensing and degrading pathways in immune regulation. 
Cytokine & growth factor reviews 35:37-45. 
2. Cobbold SP, et al. (2009) Infectious tolerance via the consumption of essential amino acids and 
mTOR signaling. Proceedings of the National Academy of Sciences of the United States of 
America 106(29):12055-12060. 
3. Zeng W, et al. (2011) A genetic screen reveals Arabidopsis stomatal and/or apoplastic defenses 
against Pseudomonas syringae pv. tomato DC3000. PLoS pathogens 7(10):e1002291. 
4. Zhang Y, et al. (2008) GCN2-dependent phosphorylation of eukaryotic translation initiation 
factor-2alpha in Arabidopsis. Journal of experimental botany 59(11):3131-3141. 
5. Magnusson LU, Farewell A, & Nystrom T (2005) ppGpp: a global regulator in Escherichia coli. 
Trends in microbiology 13(5):236-242. 
6. Braeken K, Moris M, Daniels R, Vanderleyden J, & Michiels J (2006) New horizons for 
(p)ppGpp in bacterial and plant physiology. Trends in microbiology 14(1):45-54. 
7. Haigis MC & Yankner BA (2010) The Aging Stress Response. Molecular cell 40:333-344. 
8. Fontana L, Partridge L, & Longo VD (2010) Extending Healthy Life Span-From Yeast to 
Humans. Science 328:321-326. 
9. Thomson AW, Turnquist HR, & Raimondi G (2009) Immunoregulatory functions of mTOR 
inhibition. Nature reviews. Immunology 9(5):324-337. 
10. Murray PJ (2016) Amino acid auxotrophy as a system of immunological control nodes. Nature 
immunology 17(2):132-139. 
11. Noss EH & Brenner MB (2008) The role and therapeutic implications of fibroblast-like 
synoviocytes in inflammation and cartilage erosion in rheumatoid arthritis. Immunological 
Reviews 223:252-270. 
12. Grohmann U & Bronte V (2010) Control of immune response by amino acid metabolism. 
Immunological Reviews 236:243-264. 
13. McGaha TL, et al. (2012) Amino acid catabolism: a pivotal regulator of innate and adaptive 
immunity. Immunological Reviews 249:135-157. 
14. Keller TL, et al. (2012) Halofuginone and other febrifugine derivatives inhibit prolyl-tRNA 
synthetase. Nature Chemical Biology 8:311-317. 
15. Zhou H, Sun L, Yang XL, & Schimmel P (2013) ATP-directed capture of bioactive herbal-based 
medicine on human tRNA synthetase. Nature 494(7435):121-124. 
16. Sundrud MS, et al. (2009) Halofuginone inhibits Th17 cell differentiation by activating the amino 
acid starvation response. Science 324:1334-1338. 
17. Stockinger B, Veldhoen M, & Martin B (2007) Th17 T cells: linking innate and adaptive 
immunity. Seminars in immunology 19(6):353-361. 
18. Stockinger B & Veldhoen M (2007) Differentiation and function of Th17 T cells. Current 
opinion in immunology 19(3):281-286. 
19. Filer A (2013) The fibroblast as a therapeutic target in rheumatoid arthritis. Current opinion in 
pharmacology 13(3):413-419. 
20. Bottini N & Firestein GS (2013) Duality of fibroblast-like synoviocytes in RA: passive 
responders and imprinted aggressors. Nature reviews. Rheumatology 9(1):24-33. 
21. Marton MJ, Crouch D, & Hinnebusch AG (1993) GCN1, a Translational Activator of GCN4 in 
Saccharomyces cerevisiae, is required for Phosphorylation of Eukaryotic Translation Initiation 
Factor 2 by Protein Kinase GCN2. Molecular and cellular biology 13(6):3541-3556. 
22. Vasquez de Aldana CR, Marton MJ, & Hinnebusch AG (1995) GCN20, a novel ATP binding 
cassette protein, and GCN1 reside in a complex that mediates activation of the eIF-2alpha kinase 
GCN2 in amino acid-starved cells. The EMBO journal 14(13):3184-3199. 
78 
23. Marton MJ, Vasquez de Aldana CR, Qiu H, CHakraburtty K, & Hinnebusch AG (1997) Evidence 
that GCN1 and GCN20, Translational Regulators of GCN4, Function on Elongating Ribosomes 
in Activation of eIF2⍺ Kinase GCN2. Molecular and cellular biology 17(8):4474-4489. 
24. Garcia-Barrio M, Dong J, Ufano S, & Hinnebusch AG (2000) Association of GCN1-GCN20 
regulatory complex with the N-terminus of eIF2alpha kinase GCN2 is required for GCN2 
activation. The EMBO journal 19(8):1887-1899. 
25. Sattlegger E & Hinnebusch AG (2005) Polyribosome binding by GCN1 is required for full 
activation of eukaryotic translation initiation factor 2{alpha} kinase GCN2 during amino acid 
starvation. The Journal of biological chemistry 280(16):16514-16521. 
26. Sattlegger E & Hinnebusch AG (2000) Separate domains in GCN1 for binding protein kinase 
GCN2 and ribosomes are required for GCN2 activation in amino acid-starved cells. The EMBO 
journal 19(23):6622-6633. 
27. Kubota H, Ota K, Sakaki Y, & Ito T (2001) Budding yeast GCN1 binds the GI domain to activate 
the eIF2alpha kinase GCN2. The Journal of biological chemistry 276(20):17591-17596. 
28. Hirose T & Horvitz HR (2014) The translational regulators GCN-1 and ABCF-3 act together to 
promote apoptosis in C. elegans. PLoS genetics 10(8):e1004512. 
29. Kaplan A, et al. (2017) Small-Molecule Stabilization of 14-3-3 Protein-Protein Interactions 
Stimulates Axon Regeneration. Neuron 93(5):1082-1093 e1085. 
30. Pyper SR, et al. (2010) PRIC295, a Nuclear Receptor Coactivator, Identified from PPARalpha-
Interacting Cofactor Complex. PPAR research 2010. 
31. Ebmeier CC & Taatjes DJ (2010) Activator-Mediator binding regulates Mediator-cofactor 
interactions. Proceedings of the National Academy of Sciences 107(25):11283-11288. 
32. Shao W & Espenshade PJ (2012) Expanding roles for SREBP in metabolism. Cell metabolism 
16(4):414-419. 
33. Abramson J, Giraud M, Benoist C, & Mathis D (2010) Aire's partners in the molecular control of 
immunological tolerance. Cell 140(1):123-135. 
34. Ewing RM, et al. (2007) Large-scale mapping of human protein-protein interactions by mass 
spectrometry. Molecular systems biology 3:89. 
35. Koch HB, et al. (2007) Large-scale identification of c-MYC-associated proteins using a 
combined TAP/MudPIT approach. Cell Cycle 6(2):205-217. 
36. Bandyopadhyay S, et al. (2010) A Human MAP Kinase Interactome. Nature Methods 7(10):801-
805. 
37. Jeronimo C, et al. (2007) Systematic analysis of the protein interaction network for the human 
transcription machinery reveals the identity of the 7SK capping enzyme. Molecular cell 
27(2):262-274. 
38. Lleres D, Denegri M, Biggiogera M, Ajuh P, & Lamond AI (2010) Direct interaction between 
hnRNP-M and CDC5L/PLRG1 proteins affects alternative splice site choice. EMBO reports 
11(6):445-451. 
39. Ajuh P, et al. (2000) Functional analysis of the human CDC5L complex and identification of its 
components by mass spectrometry. The EMBO journal 19(23):6569-6581. 
40. Han SJ, et al. (2016) The Dual Estrogen Receptor alpha Inhibitory Effects of the Tissue-Selective 
Estrogen Complex for Endometrial and Breast Safety. Molecular pharmacology 89(1):14-26. 
41. Cambiaghi TD, et al. (2014) Evolutionarily conserved IMPACT impairs various stress responses 
that require GCN1 for activating the eIF2 kinase GCN2. Biochemical and biophysical research 
communications 443(2):592-597. 
42. Herman JD, et al. (2015) The cytoplasmic prolyl-tRNA synthetase of the malaria parasite is a 
dual-stage target of febrigugine and its analogs. Science Translational Medicine 7(288). 
43. Gantke T, Sriskantharajah S, Sadowski M, & Ley SC (2012) IkB kinase regulation of the TPL-
2/ERK MAPK pathway. Immunological Reviews 246:168-182. 
79 
44. Furusawa T, Moribe H, Kondoh H, & Higashi Y (1999) Identification of CtBP1 and CtBP2 as 
Corepressors of Zinc Finger-Homeodomain Factor δEF1. Molecular and cellular biology 
19(12):8581-8590. 
45. Dean M & Annilo T (2005) Evolution of the ATP-binding cassette (ABC) transporter 
superfamily in vertebrates. Annual review of genomics and human genetics 6:123-142. 
46. Rossi A, et al. (2015) Genetic compensation induced by deleterious mutations but not gene 
knockdowns. Nature 524(7564):230-233. 
47. El-Brolosy MA & Stainier DYR (2017) Genetic compensation: A phenomenon in search of 
mechanisms. PLoS genetics 13(7):e1006780. 
48. Nakamura A & Kimura H (2017) A new role of GCN2 in the nucleolus. Biochemical and 
biophysical research communications 485(2):484-491. 
49. David A, et al. (2012) Nuclear translation visualized by ribosome-bound nascent chain 
puromycylation. The Journal of cell biology 197(1):45-57. 
50. Kramer EB & Hopper AK (2013) Retrograde transfer RNA nuclear import provides a new level 
of tRNA quality control in Saccharomyces cerevisiae. Proceedings of the National Academy of 
Sciences 110(52):21042-21047. 
51. Plevin MJ, Mills MM, & Ikura M (2005) The LxxLL motif: a multifunctional binding sequence 
in transcriptional regulation. Trends in biochemical sciences 30(2):66-69. 
52. Folco EG, Lei H, Hsu JL, & Reed R (2012) Small-scale nuclear extracts for functional assays of 
gene-expression machineries. Journal of visualized experiments : JoVE (64). 
 
 
 
 
  
80 
  
81 
CHAPTER FOUR 
 
Characterization of a Novel Mammalian Nutritional Stress Response Pathway   
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INTRODUCTION 
 
In the previous chapter I determined that the evolutionarily conserved protein, GCN1, is required for 
GCN2-dependent AAR pathway signaling in mammalian cells. I also found that GCN1 is required for 
GCN2-independent changes in key regulators of arthritis tissue remodeling induced by HF treatment in 
TNFα-stimulated cells.  To investigate more generally how GCN1 might mediate HF effects on 
transcriptional programs, I next used unbiased transcriptomic analysis to compare HF effects in wild type 
FLS versus GCN1-knockdown or GCN2-knockdown FLS. Although we know GCN1 mediates these 
GCN2-independent effects, we do not know whether GCN1 mediates additional GCN2-independent 
effects or functions, or whether GCN1 mediates GCN2-independent effects in the absence of an 
inflammatory signal.  The previous chapter looked at GCN1 activity in the absence of an inflammatory 
signal in non-FLS cell types. In this chapter, we return to our in vitro FLS system, in which we know 
GCN1 regulates transcription of several genes independently of GCN2.  With this system, we use 
transcriptomic analysis to characterize the entire transcriptional program mediated by GCN1 upon HF 
treatment in both the presence and absence of TNFα revealing a substantial portion of AAR 
transcriptional changes are regulated by GCN1 independently of GCN2 in the presence and absence of an 
inflammatory stimulus. 
 
How GCN1 might mediate GCN2 independent effects remains unknown.  In the previous chapter, I tested 
the possibility, suggested by prior literature, that GCN1 might interact with nuclear regulators, and 
whether HF could change the subcellular distribution of GCN1. My studies of GCN1 nuclear localization 
and interaction were inconclusive, but differential extraction studies suggested that HF might indeed 
change GCN1 distribution. I therefore sought: 1) to further examine HF effects on GCN1 distribution, 
focusing on the ribosomal fraction, in which GCN1 is known to function in yeast; 2) to use unbiased mass 
spec based interactomics to identify GCN1 interactors that can subsequently be tested as candidate 
mediators of HF signaling to the GCN1-regulated transcriptional program identified in my transcriptomic 
analysis. In my nuclear immunoprecipitation of endogenous GCN1 from HeLa cells (chapter 3), I found 
that commercially available GCN1 antibodies interacted non-specifically with nuclear proteins, and 
therefore significantly compromised experimental interpretation. Moving forward, I developed cells 
expressing a knocked-in GCN1 gene with an epitope tag to allow immuno-isolation studies with an anti-
epitope antibody. This technical improvement allows future interactomic studies to be performed, while 
minimizing the issues of commercial antibodies to endogenous GCN1 cross-reacting non-specifically 
with cellular proteins. In these experiments, I will examine HF-treatment driven changes in GCN1 protein 
associations in TNFα-treated FLS, to better understand which of these changes can be linked causally to 
therapeutic inflammatory suppressive effects of the newly discovered nutritional stress response pathway. 
 
RESULTS 
 
GCN1 is required for HF transcriptional regulation with a large portion independent of GCN2 
We know GCN1 mediates GCN2-dependent AAR pathway signaling and GCN2-independent inhibition 
of several therapeutic pro-inflammatory genes but we do not know what additional effects this branch 
point has or if the new branch functions outside an inflammatory context.  To characterize the full 
transcriptional program regulated by GCN1 independently of GCN2 we compared changes in global 
mRNA expression between shRNA-mediated knockdown control, GCN1, and GCN2 K4 cells treated 
with and without HFol in the presence or absence of the inflammatory cytokine, TNFα. Fewer genes were 
differentially expressed upon HFol treatment in GCN1- and GCN2-knockdown cells compared to control 
knockdown cells consistent with a role for GCN1 and GCN2 in HF transcriptional regulation (Table 1).  
7,521 genes were differentially expressed by HFol treatment in control cells compared to only 4,373 and 
6,256 in GCN1- and GCN2-knockdown cells, respectively (Table 1, Fig S1). Similar levels of genes 
were significantly differentially expressed by TNFα treatment across cell types indicating GCN1 and 
GCN2 knockdown did not globally alter TNFα response (Table 1, Fig S1 Fig 1c).   
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Both in the presence and absence of TNFα, GCN1 was required for essentially all transcriptional 
regulation by HFol treatment including GCN2-dependent and -independent changes, while GCN2 was 
required for a smaller portion of these changes (Fig 1a-b).  In GCN1-knockdown cells, there was little 
transcriptional regulation by HFol.  A much smaller number of genes were differentially expressed upon 
HFol treatment in GCN1 knockdown cells compared to control cells and those genes that were 
differentially expressed exhibited a large decrease in magnitude in their fold change.  The number of 
genes differentially expressed by HFol treatment decreased by almost 2 fold compared to control cells 
and the proportion of differentially expressed genes changing over 2 fold by HFol treatment fell from 
18.7% to 1.2% (Fig 1a-b, Table 1, Fig S1). Similar changes occurred in the presence or absence of TNFα 
(Fig 1a-b, Table 1, Fig S1).   In contrast, the number of differentially expressed genes upon HFol 
treatment in GCN2-knockdown cells compared to control cells was decreased by less than 1/5 compared 
to control cells in the absence of TNFα (Fig 1a-b, Table 1, Fig S1).  Unexpectedly, in the presence of 
TNFα, the number of differentially expressed genes in GCN2-knockdown cells was greater than in 
control cells; however, this is consistent with previous observations by qPCR (Table 1, qPCR data not 
shown).  These results confirm that GCN1 mediates both GCN2 dependent and independent 
transcriptional changes by HF, validating GCN1 as a branch point in the AAR.  Notably, GCN1 mediates 
a large transcriptional program independent of GCN2 in both the presence and absence of TNFα. 
 
In the presence of TNFα, previously identified GCN1-dependent, GCN2-independent genes such as 
CXCL10, MMP13, and IDO1 were regulated as expected i.e. only inhibited by HFol in control and 
GCN2-knockdown cells.  Additional genes revealed within the transcriptomics as GCN1-dependent and 
GCN2-independent in the presence of TNFα included chemokines, cytokines, cell surface proteins (e.g. 
cadherin 5, type 2, lectin), transcriptional regulators (e.g. ZMYND15, BATF2), and genes involved in 
blood vessel development and ECM remodeling consistent with known therapeutic activities of HF.  
Notably, in the absence of TNFα stimulation, GCN1-dependent but GCN2-independent differentially 
expressed genes by HFol were significantly enriched in gene ontology terms related to cholesterol and 
steroid metabolic processes, while GCN2-dependent differentially expressed genes were not (Table S2-
3).   
 
HF treatment shifts GCN1 out of the ribosome fraction 
GCN1 clearly mediates a large set of GCN2-independent transcriptional effects but we still don’t know 
how. In the previous chapter immunofluorescence analysis suggested that most if not all mammalian 
GCN1 resides in the cytoplasm.  In yeast, GCN1 interacts with translating ribosomes and ribosomal 
association is required for GCN1 mediation of the uncharged tRNA signal to GCN2 (1, 2).  To determine 
whether HF alters GCN1 association with ribosomes in mammals, we lysed untreated or HF treated K4 
cells with digitonin to obtain a cytoplasmic cell fraction, and spun this fraction through a sucrose cushion 
to obtain a crude ribosomal pellet, which we then analyzed by immunoblot.  As expected, ribosomal 
proteins L13a and L7a were concentrated in the pellet, while cytoplasmic proteins such as GAPDH were 
almost undetectable in the pellet (Fig 2a).  HF treatment decreased GCN1 in the ribosomal pellet but did 
not alter ribosomal protein levels demonstrating that HF shifts GCN1 out of the ribosomal fraction.  In 
yeast, ATP enhances GCN1 association with polysomes.  Likewise, the presence of ATP increased GCN1 
in the ribosomal pellet (Fig 2a).  Notably GCN2 and ABCF3, whose orthologs are known to interact with 
GCN1 in yeast, exhibited patterns similar to GCN1 across ribosomal pellets, while HF’s target, EPRS 
was not similarly distributed (Fig 2a). Cycloheximide treatment, which results in stalled ribosomes, 
increased GCN1 in the ribosomal pellet indicating that GCN1 in the ribosomal pellet is associated with 
the ribosome (Fig S2).  In yeast, GCN1 physically interacts with the small ribosomal protein S10 (Rps10) 
and Rps10 mutant strains show reduced eIF2α phosphorylation under nutrient replete conditions and 
within a few minutes of amino acid starvation suggesting this interaction is involved in GCN1 function 
(3).  Mammalian GCN1 likewise co-precipitated with mammalian Rps10 and HF treatment decreased 
GCN1 interaction with Rps10 consistent with the shift of GCN1 out of the ribosomal fraction with HF 
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treatment (Fig 2b).  Together this suggests that upon uncharged tRNA stimulation, GCN1 is released 
from the ribosome to mediate functions away from the ribosome.   
 
Does HF change GCN1 interactions in cytoplasmic and/or ER/Nuclear fractions? 
We know GCN1 is released from the ribosome upon HF treatment, suggesting GCN1 distribution within 
the cell plays a role in mediating GCN1 branch functions.  Since GCN1 was not observed in the nucleus, 
but putatively interacts with a set of proteins distinct from its GCN2 function and enriched in nuclear 
regulators, GCN1 likely mediates its functions by interacting with other proteins. To determine what 
GCN1 is interacting with, where these interactions are taking place, and whether these interactions are 
regulated by the AAR we set up an unbiased approach to pull down GCN1 and identify GCN1 protein 
interactors by TMT-MS analysis from different cell fractions under conditions that recapitulate the 
conditions in which we have characterized a full transcriptional readout of this novel branch. 
 
Knock-in cells allow specific and efficient pull down of GCN1 
In the previous chapter, immunoprecipitation of endogenous GCN1 from nuclear extracts revealed that 
commercial GCN1 antibody was not specific enough to reliably pull down GCN1 to identify interactors.  
Instead, we generated HA-tagged GCN1 expressing K4 cells via CRISPR knock-in, to allow us to 
specifically immunoprecipite GCN1 with HA antibody from the same cells and conditions in which we 
have now characterized a complete transcriptional program mediated by the GCN1 branch.  The 
distribution of HA-GCN1 expression across sequentially extracted cell fractions and ribosomal pellets 
was similar to the distribution of endogenous GCN1, although changes with HF were less noticeable, 
suggesting tagged-GCN1 behaves similarly to endogenous GCN1 (Fig S3).  
 
Identification of protein components of the GCN1-dependent, GCN2-independent pathway 
To determine protein interactors we treated knock-in K4 cells with and without HF in the presence of 
TNFα to recapitulate conditions under which we know the GCN1 mediates GCN2-independent functions.  
HA-GCN1 was immunoprecipitated from digitonin and NP/40 high salt fractions and sent for TMT-MS 
analysis, to identify and quantify all proteins interacting with GCN1 under these conditions. Silverstain of 
these bands confirmed several protein bands specific to GCN1 immunoprecipitation (Fig 3).  A subset of 
these bands changed with HF treatment, suggesting these bands are GCN1 protein interactors regulated 
by HF treatment. 
 
DISCUSSION 
 
GCN1 is a major mediator of uncharged tRNA effects 
In this chapter we use unbiased approaches to identify both downstream transcriptional effects and 
upstream protein mediators of the GCN2-independent GCN1 branch.  In the previous chapter, we found 
that GCN1 represents a branch point in the mammalian AAR, required for GCN2 pathway activation and 
for several previously identified GCN2-independent transcriptional effects.  Transcriptomic comparison 
of HF treated control, GCN1-, and GCN2-knockdown K4 confirm GCN1 is a branch point in the AAR, 
whose GCN2-independent branch is a major mediator of transcriptional changes triggered by uncharged 
tRNA.  Our transcriptomics show that in both the presence and absence of TNFα, GCN1 is required for 
pretty much all HF transcriptional changes including GCN2-independent changes, and GCN2-dependent 
changes are only a fraction of the total changes mediated by GCN1.  A subset of the transcriptional 
changes observed will need to be confirmed in independent experiments by qPCR.  If GCN1 and GCN2 
knockout K4 can be generated, dependence on GCN1 and GCN2 can be clearly evaluated.  In addition, 
the broader set of GCN1-dependent, GCN2-independent HF-regulated genes identified here, including 
ones occurring in the absence of TNFα may allow the use of other cells to confirm and functionally study 
the pathway, such as HCT116, in which GCN1 and GCN2 knockouts have been generated.  In addition, 
these genes will provide readouts for study of this new pathway outside the inflammatory context.  This 
data reveals not only what functions this GCN2-independent branch mediates, but patterns and 
86 
characteristics of the regulated genes will provide clues for upstream regulators that function between 
GCN1 and these transcriptional changes.  Comparison to transcriptional programs regulated by HF in 
other cell types will provide further clues into possible master regulators involved in the GCN2-
independent branch across cell types. 
 
How does GCN1 function? 
GCN1 clearly mediates important transcriptional effects independently of GCN2, but we do not know 
how.  To begin to understand what is happening between GCN1 and its transcriptional effects we looked 
upstream of transcription, to whether HF treatment induced changes to GCN1 itself, in particular whether 
HF changed its localization and its protein interactors.  We found that HF treatment both shifts GCN1 out 
of the ribosomal fraction and decreases its interaction with the ribosomal protein, Rps10. This suggests 
HF releases GCN1 from the ribosome, potentially allowing GCN1 to mediate functions away from the 
ribosome.  We previously observed in sequential cell fractionations that HF treatment shifts GCN1 into 
the digitonin fraction and out from the NP-40 and high salt fractions.  This would be consistent with the 
release of GCN1 from the ribosome upon increased levels of uncharged tRNA, which would include 
release of GCN1 into the digitonin-soluble cytoplasmic fraction from NP-40 soluble ER-bound 
ribosomes.  Interestingly, ATP also increased GCN1 in the ribosomal pellet.  In yeast, ATP increases 
GCN1 association with the ribosome in a GCN20-dependent fashion, although the functional significance 
is unknown (1).  However, in the previous chapter we showed that ABCF3 was not required for HF-
induced GCN2 pathway activation or transcriptional inhibition of several GCN2-independent genes by 
HF treatment.  In addition, both ABCF3 and GCN2 were regulated by HF and ATP similarly to GCN1, 
suggesting they may form a complex with GCN1, as they do in yeast. What role ABCF3 plays, especially 
with respect to the findings of the previous chapter, will need to be further tested. 
 
GCN1 likely interacts with currently unknown proteins to mediate its GCN2-independent functions.  The 
optimized system introduced in this chapter will not only identify interactions in an unbiased manner, but 
will indicate whether HF regulates these interactions.  If an interaction is changed by HF and 
independently confirmed, knockdown or knockout cell lines for the protein of interest can be used to 
determine whether the interaction is required for regulating transcriptional changes characterized earlier 
in this chapter.  The known functions of identified proteins will also likely provide functional insight.  
Once these interactions are identified we can determine if there is any overlap with our putative list of 
nuclear GCN1 interactors from the last chapter or putative GCN1 interactors identified in previous studies 
(e.g. ABCF3, mediator complex).  Our optimized system will further determine whether interactions 
occur in the digitonin-soluble cytoplasm associated fraction or the NP-40/high salt ER/nuclear associated 
fraction, which will indicate whether GCN1 localization regulates or promotes certain protein interactions 
as well as provide potential protein regulators of GCN1 localization.  In addition, since GCN1 mediates 
GCN2-independent effects triggered by uncharged tRNA another uncharged tRNA sensor must exist.  
Either GCN1 is an uncharged tRNA sensor directly binding uncharged tRNA itself or GCN1 may 
function as a scaffold for a currently unidentified uncharged tRNA sensor.  Protein interactors identified 
here will provide candidates for this function, which can be further tested.  The non-canonical GCN1 
branch plays a large role in the mammalian cellular response to uncharged tRNA, previously only thought 
to consist of the GCN2 pathway.  This chapter identifies both downstream transcriptional effects and sets 
up a system to identify upstream mediators of this previously unidentified pathway to begin to understand 
its functions and mechanisms. 
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METHODS 
 
Reagents  
As described in chapter three.  Additional reagents used in this chapter are listed below. 
ANTIBODIES: L7a (CST 2415), L13a (CST 2765S), EPRS (Abcam ab31531) 
 
Cell Lines and Cell Culture 
As described in chapter three.  
 
cDNAs 
pCSX-HA-GCN1 (N-terminal tag): 
pAAVS1-puro-DNR-HA-GCN1 (N-terminal tag): PmeI and NheI used to clone HA-GCN1 from pCSX-
HA-GCN1 and into pAAVS1-puro-DNR (with previously modified multiple cloning site). 
 
Generation of HA-GCN1 K4 stable cell line 
HA-GCN1 was knocked into the AAVS1 genomic locus in K4 cells by CRISPR using the AAVS1 
Transgene knockin vector kit according to manufacturer’s protocol (Origene GE100027).  K4 cells were 
transiently transfected with pCas-Guide-AAVS1 and pAAVS1-puro-DNR-HA-GCN1 and then 
maintained through 8 passages to dilute out non-integrated puromycin-resistant plasmid DNA.  Cells 
were then puromycin selected and propagated. 
 
RNAseq sample collection and preparation 
shRNA-mediated scrambled, GCN1, and GCN2 knockdown K4 cells (described in chapter three) were 
generated and obtained from Yeon-Jin Kim.  Cells were starved in 0.2% FBS K4 media for 24 hours.  
Cells were then treated with 250 nM HFol or equivalent volume of DMF for 24 hours with or without 
addition of 10 ng/mL TNFα 8 hours prior to RNA harvest.  Biologicial duplicates were collected for each 
condition for a total of 24 samples.  RNA quantity and quality was checked using a Bioanalyzer at the 
Biopolymers Facility, Harvard Medical School.  Poly-A enriched libraries were prepared with the TruSeq 
Stranded mRNA Library Prep Kit, sequenced using a single-end approach with 100 bp reads at a total 
sequencing depth of 30 million reads on an Illumina 4000 instrument, and mapped to the genome by the 
JP Sulzberger Columbia Genome Center.  Pairwise DEseq2 analysis of differentially expressed genes was 
performed on the Galaxy web platform (4).  Gene ontology term enrichment was performed using 
STRING, v10.5 (5) 
 
Sucrose density centrifugation to isolate ribosomal pellets 
K4 cells grown on 10 cm dishes were sequentially extracted by digitonin and NP-40 as described in 
chapter three but with an additional 2.5 mM MgCl2 added to the digitonin buffer, 20 U/mL of RNase 
inhibitor added to all lysis buffers, and lysed in a volume of 3 mL.  Protease and phosphatase inhibitors 
were added to all buffers.  3 mL lysate was layered over a 1.5 mL 1M sucrose cushion (1 M sucrose, 110 
mM KOAc, 25 mM KHEPES, pH 7.2, 5 mM MgCl2, 1 mM EGTA), and centrifuged at 250,000 G for 2 
hours at 4C in a Beckman-Coulter Optima XE-100 Ultracentrifuge with the Beckman-Coulter SW 55 Ti 
Rotor.  The pellet was washed with 4.5 mL wash buffer (110 mM KOAc, 25 mM KHEPES, pH 7.2, 5 
mM MgCL2, 1 mM EGTA, 100 mM sucrose) and centrifuged at 250,000G for another 30 minutes.  The 
supernatant was carefully removed and the ribosomal pellet was re-suspended in 100 uL 0.1% NP-40 
buffer (0.1% NP-40, 110 mM KOAc, 25 mM KHEPES, pH 7.2, 5 mM MgCL2, 1 mM EGTA). 
 
Rps10 Co-IP 
HA-GCN1 knockin K4 cells were treated with or without 500 nM HF for one hour and then all cells were 
treated with 100 ug/mL cycloheximide for 4 minutes.  Cells were digitonin permeabilized as described 
above with RNase inhibitor and ATP.  After lysis NP-40 was added to lysate for a final concentration of 
0.1%.  HA immunoprecipitation and elution were performed as described below. 
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GCN1 pull down for TMT-MS 
HA-GCN1 knockin K4 cells grown on 10 cm dishes were starved in 0.2% FBS K4 media for 24 hours.  
All cells were then treated with 10 ng/mL TNFα.  After 3 hours, 500 nM HF was added to HF treated 
cells, and after another 26 minutes all cells were treated with 100 ug/mL cycloheximide for 4 minutes and 
then sequentially extracted by digitonin and NP-40/high salt as previously described with the following 
modification.  For NP-40/high salt lysis, cells were scraped in 1 mL NP-40/high salt lysis buffer into 
microcentrifuge tubes, incubated for 10 minutes at 4C, centrifuged to remove cellular debris, and diluted 
with 4 mL dilution buffer (1% NP-40, 50 mM KHEPES, pH 7.2, 30 mM MgCl2).  Lysates were 
incubated with magnetic HA beads (Pierce) for 3 hours at 4C in siliconized tubes.  Beads pre-incubated 
with HA peptide were used as control.  Beads were washed 3x with lysis buffer and 1x with 0.1% NP-40 
PBS.  Four 10 cm plates were pooled for each condition and each condition was performed in duplicate.  
Beads were eluted with PGB without bromophenol blue for 20 minutes at room temperature as described 
for the nuclear IP-MS in chapter three.  10% of each sample was run on the gel in figure 3 for 
silverstaining and the rest was sent to the Thermo Fisher Center for Multiplexed Proteomics, Harvard 
Medical School for quantitative protein identification by TMT-MS analysis.  
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Fig 1 | GCN1 is required for most if not all HFol regulated mRNA expression, while GCN2 is 
required for only a portion of HFol regulated mRNA expression.  (a) Heatmap of average fold change 
by HFol treatment relative to untreated in shRNA mediated control, GCN1, and GCN2 knockdown K4. 
(b)  Heatmap of average fold change by HFol treatment with TNFα stimulation relative to TNFα 
treatment alone.  (c) Heatmap of average fold change by TNFα treatment relative to untreated.  In all 
heatmaps only genes with values that changed over 2.5 fold in control cells were mapped. 
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Fig	2	|	GCN1	is	required	for	most	if	not	
all	HF	regulated	mRNA	expression,	
while	GCN2	is	required	for	only	a	
porFon	of	HF	regulated	mRNA	
expression.		(a)	Heatmap	of	average	fold	
change	by	HF	treatment	rela(ve	to	
untreated	in	shRNA	mediated	control,	
GCN1,	and	GCN2	knockdown	K4.	(b)		
Heatmap	of	average	fold	change	by	HF	
treatment	with	TNFα	s(mula(on	rela(ve	
to	TNFα	treatment	alone.		(c)	Heatmap	
of	average	fold	change	by	TNFα	
treatment	rela(ve	to	untreated.		In	all	
heatmaps	only	genes	with	values	that	
changed	over	2.5	fold	in	control	were	
mapped.	
(a)	 (b)	 (c)	
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Table 1 | Significantly differentially expressed genes.  Genes were considered differentially expressed 
if pAdj < 0.05.  Control is shRNA-mediated scrambled knockdown K4, shGCN1 is shRNA-mediated 
GCN1 knockdown K4, and shGCN2 is shRNA-mediated GCN2 knockdown K4. 
 
 
 
 
 
Fig 2 | HF treatment shifts GCN1 out of ribosome fraction and decreases GCN1 interaction with 
the small ribosomal protein, Rps10. (a) Digitonin and NP-40 extracts from K4 cells treated with and 
without HF and harvested in the presence of absence of 5 mM ATP were layered over a sucrose cushion 
and centrifuged at high speed.  The pellet was re-suspended and analyzed by immunoblot for the 
indicated proteins. (b) GCN1 from stable HA-GCN1 knockin K4 was immunoprecipitated by HA 
antibody-linked beads and assayed for Rps10 and HA-GCN1 protein by immunoblot.  HA peptide 
blocked beads were used as control.  HF treatment data in (a) is representative of at least 3 separate 
experiments.  ATP treatment compared to no ATP treatment was tested only in this single experiment.  
Data in (b) is representative of 3 separate experiments. 
Cell	type	 Diﬀeren-ally	expressed	genes	
Diﬀeren-ally	expressed	
genes	with		
change	>	2	fold	
HFol	treated	versus	untreated	
control	 7521	 1409	
shGCN1		 4373	 52	
shGCN2	 6256	 808	
TNFα	treated	versus	untreated	
control	 6899	 1792	
shGCN1	 6354	 1374	
shGCN2	 6190	 1625	
HFol/TNFα	treated	versus	TNFα	treated	
control	 7603	 1362	
shGCN1	 4355	 54	
shGCN2	 8140	 1904	
Table	1	|	Signiﬁcantly	diﬀeren-ally	expressed	genes.		
Genes	are	considered	diﬀeren<ally	expressed	if	pAdj	<	
0.05.		Control	is	shRNA-mediated	scrambled	
knockdown	K4,	GCN1	kd	is	GCN1	knockdown	K4,	and	
GCN2	kd	is	GCN2	knockdown	K4.	
-		+			-		+			-		+			-		+		-			+		-		+			-		+			-		+	
ATP	 ATP	 ATP	 ATP	
DIGITONIN	 DIGITONIN	NP-40	 NP-40	
INPUT	 Ribosomal	pellet	
GCN1	
L13a	
ABCF3	
GAPDH	
EPRS	
GCN2	
L7a	
HF	(300	nM):	
Fig	1a	|	HF	treatment	shiGs	GCN1	out	of	ribosome	fracKon	and	decreases	GCN1	interacKon	with	the	small	ribosomal	protein,	Rps10.	(a)	
Digitonin	and	NP-40	extracts	from	K4	cells	treated	with	and	without	HF	and	ATP	were	layered	over	a	sucrose	cushion	and	centrifuged	at	high	
speed.		The	pellet	was	re-suspended	and	analyzed	by	immunoblot	for	the	indicated	proteins.	(b)	GCN1	from	stable	HA-GCN1	knockin	K4	was	
immunoprecipitated	by	HA	anNbody	linked	beads	and	assayed	for	Rps10	and	HA-GCN1	protein	by	immunoblot.		HA	pepNde	blocked	beads	were	
used	as	control.	
VII:83	
9.28.17	
KEY:	
C	=	HA	blocked	beads	control	
C	Input	
HA	IP	
Rps10	
HA	(GCN1)	
-			+		-			-		+	HF	(500	nM):	
(a)	 (b)	
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Fig 3 | Optimized unbiased IP-MS approach to identify GCN1 interactors shows proteins specific to 
GCN1 pulldown changed by HF treatment.  Silverstained protein gels comparing proteins precipitated 
by epitope tag pull down of GCN1 from non-treated and HF treated HA-GCN1 knockin K4 in the 
presence of TNFα.  Cells were sequentially fractionated, first by digitonin, and then by NP-40/high salt, 
and GCN1 immunoprecipitated from each fraction (left panel) Digitonin fraction. (right panel) NP-
40/high salt fraction.  White arrow head indicates band at size of full length GCN1.  Grey arrow heads 
indicate bands specific to GCN1 pull down, while black arrow head indicates a band appearing only with 
HF treatment. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
HF	 HF	
HA	pep&de	
Control	
HA	IP	
DIGITONIN	Frac&on:	
Fig	3	|	Op-mized	unbiased	IP-MS	approach	to	iden-fy	GCN1	interactors	shows	proteins	speciﬁc	to	GCN1	pulldown	changed	by	HF	treatment.		
Silverstained	protein	gels	comparing	proteins	precipitated	by	epitope	tag	pull	down	of	GCN1	from	non-treated	and	HF	treated	HA-GCN1	knockin	
in	K4	in	the	presence	of	TNFα.		Cells	were	sequen&ally	frac&onated,	ﬁrst	by	digitonin,	and	then	by	NP-40/high	salt,	and	GCN1	
immunoprecipitated	from	each	frac&on	(leR	panel)	Digitonin	frac&on.	(right	panel)	NP-40/high	salt	frac&on.		White	arrow	head	indicates	band	at	
size	of	full	length	GCN1.		Grey	arrow	heads	indicate	bands	speciﬁc	to	GCN1	pull	down,	while	black	arrow	head	indicates	a	band	appearing	only	
with	HF	treatment.	
NP-40/HS	Frac&on:	
HF	 HF	
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Control	
HA	IP	
input	input	
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Fig S1 | MA plots for pairwise DESEQ2 analyses.  Fold changes of all genes plotted against normalized 
expression.  Red dots show genes whose fold changes were statistically significant.  Note y-axes display 
different ranges.  Dashed blue lines mark 1 and -1 on the y-axis for orientation. 
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Fig	S1	|	MA	plots	for	pairwise	DESEQ2	analyses.		Fold	
changes	of	all	genes	plo8ed	against	normalized	
expression.		Red	dots	show	genes	whose	fold	changes	
were	signiﬁcant.		Note	y	axes	display	diﬀerent	ranges.		
Dashed	blue	lines	mark	1	and	-1	for	orientaHon.	
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Table S1 | Functional enrichments of most HF regulated genes in the absence of TNFα.  Genes with 
over 2 fold change in expression with HF treatment compared to non treated in control cells.   
pathway	description
observed	gene	
count
false	discovery	
rate
cholesterol	biosynthetic	process 10 7.52E-08
cholesterol	metabolic	process 13 7.71E-07
immune	system	process 48 1.58E-05
defense	response 38 4.60E-05
immune	response 36 7.18E-05
response	to	stress 65 0.000114
immune	effector	process 19 0.00018
steroid	metabolic	process 14 0.000206
organic	hydroxy	compound	metabolic	process 20 0.000206
receptor-mediated	endocytosis 12 0.000975
regulation	of	apoptotic	process 34 0.000975
intrinsic	apoptotic	signaling	pathway	in	response	to	ER	stress 6 0.000975
regulation	of	cell	death 35 0.00124
organic	hydroxy	compound	biosynthetic	process 11 0.00196
small	molecule	biosynthetic	process 16 0.00206
innate	immune	response 26 0.00206
alcohol	metabolic	process 15 0.00252
response	to	stimulus 98 0.00361
defense	response	to	virus 10 0.0038
type	I	interferon	signaling	pathway 7 0.0041
cellular	response	to	type	I	interferon 7 0.0041
response	to	external	stimulus 39 0.00421
vasculature	development 17 0.00474
apoptotic	process 27 0.0053
single-organism	process 133 0.0053
single-organism	cellular	process 128 0.00602
regulation	of	response	to	stimulus 57 0.00604
positive	regulation	of	biological	process 76 0.00781
blood	vessel	development 16 0.00842
positive	regulation	of	response	to	stimulus 38 0.0109
response	to	biotic	stimulus 20 0.0137
response	to	unfolded	protein 9 0.0141
programmed	cell	death 26 0.0141
negative	regulation	of	cell	proliferation 19 0.0149
response	to	other	organism 19 0.0214
response	to	nitrogen	compound 22 0.0222
isoprenoid	biosynthetic	process 4 0.0309
negative	regulation	of	interleukin-2	secretion 2 0.0343
positive	regulation	of	I-kappaB	kinase/NF-kappaB	signaling 9 0.0349
positive	regulation	of	cysteine-type	endopeptidase	activity	
involved	in	apoptotic	signaling	pathway 4 0.0349
anatomical	structure	development 63 0.0356
activation	of	immune	response 14 0.0386
cellular	response	to	interferon-alpha 3 0.0386
response	to	organonitrogen	compound 20 0.0403
cell	communication 73 0.0405
endoplasmic	reticulum	unfolded	protein	response 7 0.0405
system	development 56 0.0438
signal	transduction 68 0.0462
cellular	response	to	unfolded	protein 7 0.0462
positive	regulation	of	apoptotic	process 16 0.0462
cellular	response	to	biotic	stimulus 8 0.0488
regulation	of	blood	pressure 8 0.0498
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Table S2 | Functional enrichments of GCN1 dependent, GCN2 independent genes in the absence of 
TNFα.  From genes with over 2 fold change in expression with HF treatment compared to non treated in 
control cell, designated them as GCN1 dependent/GCN2 independent if there was over a 2 fold change 
between the fold change in control versus shGCN1 knockdown cells, and over a 2 fold change in 
shGCN1 knockdown cells versus shGCN2 knockdown cells.  About 88 genes. 
 
 
 
 
 
Table S3 | Functional enrichments of GCN2 dependent genes in the absence of TNFα.  From genes 
with over 2 fold change in expression with HF treatment compared to non treated in control cell, 
designated them as GCN2 dependent if there was over a 2 fold change between the fold change in control 
versus shGCN2 knockdown cells.  About 130 genes. 
 
 
 
pathway	description
observed	gene	
count
false	discovery	
rate
cholesterol	biosynthetic	process 7 1.51E-06
cholesterol	metabolic	process 9 1.82E-06
steroid	metabolic	process 10 5.11E-05
vasculature	development 10 0.0151
organic	hydroxy	compound	metabolic	process 10 0.0166
blood	vessel	development 9 0.0479
isopentenyl	diphosphate	biosynthetic	process,	mevalonate	
pathway 2 0.0479
pathway	description
observed	gene	
count
false	discovery	
rate
defense	response 27 1.69E-05
immune	system	process 31 4.78E-05
immune	response 24 0.00015
immune	effector	process 14 0.00017
type	I	interferon	signaling	pathway 7 0.00017
cellular	response	to	type	I	interferon 7 0.00017
defense	response	to	virus 9 0.000274
response	to	stimulus 59 0.00075
innate	immune	response 18 0.00163
response	to	stress 37 0.00207
response	to	other	organism 15 0.00207
cytokine-mediated	signaling	pathway 11 0.00446
response	to	external	stimulus 24 0.0135
cellular	response	to	interferon-alpha 3 0.0147
interferon-gamma-mediated	signaling	pathway 5 0.0186
negative	regulation	of	interleukin-2	secretion 2 0.0209
signal	transduction 41 0.0363
cell	surface	receptor	signaling	pathway 24 0.0454
cellular	response	to	stimulus 48 0.046
cell	communication 43 0.0473
cellular	response	to	molecule	of	bacterial	origin 6 0.0481
cellular	response	to	cytokine	stimulus 11 0.0481
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Fig S2 | Cycloheximide treatment increases GCN1 levels in the ribosome fraction.  K4 cells treated 
with and without 100 ug/mL cycloheximide for 4 minutes were digitonin lysed in the presence of ATP.  
The lysate was layered over a sucrose cushion and centrifuged at high speed.  The pellet was re-
suspended and analyzed by immunoblot for the indicated proteins.  Data are representative of a single 
experiment. 
 
 
 
 
 
Fig S3 | HA-GCN1 is distributed similarly to endogenous GCN1 by biochemical fractionation and 
sucrose cushion centrifugation. (a) Tagged and endogenous levels of GCN1 were compared by 
immunoblot across digitonin sequential extraction between wildtype K4 and stable HA-GCN1 knockin 
K4 treated with and without HF.  (b) Tagged and endogenous levels of GCN1 were compared between 
ribosomal pellets of wildtype K4 and stable HA-GCN1 knockin K4 treated with and without HF.  Data 
are representative of a single experiment. 
VII:60	
8.21.17	
Fig	S2	|	Cycloheximide	treatment	increases	GCN1	levels	in	the	ribosome	frac=on.		K4	cells	treated	with	and	without	100	ug/mL	
cycloheximide	for	4	minutes	were	digitonin	lysed	in	the	presence	of	ATP.		The	lysate	was	layered	over	a	sucrose	cushion	and	centrifuged	at	
high	speed.		The	pellet	was	re-suspended	and	analyzed	by	immunoblot	for	the	indicated	proteins.	
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Fig	S2	|	HA-GCN1	is	distributed	similarly	to	endogenous	GCN1	by	biochemical	frac=ona=on	and	sucrose	cushion	centrifuga=on.	(a)	Tagged	and	
endogenous	levels	of	GCN1	were	compared	by	immunoblot	across	digitonin	sequen`al	extrac`on	between	wildtype	K4	and	stable	HA-GCN1	
knockin	K4	treated	with	and	without	HF.		(b)	Tagged	and	endogenous	levels	of	GCN1	were	compared	between	ribosomal	pellets	of	wildtype	K4	
and	stable	HA-GCN1	knockin	K4	treated	with	and	without	HF.	
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CONCLUSIONS 
 
This thesis describes the discovery of a novel nutritional stress response pathway in mammalian cells that 
utilizes components of the AAR pathway upstream of GCN2, including the scaffold-like protein GCN1.  
The AAR pathway is part of the larger ISR in mammals, which consists of multiple branches triggered by 
distinct stresses, which share phospho-eIF2α signal generation, but each also has a unique cellular 
response due to activation of parallel pathway(s) by the initiating stress (1-5).  No parallel pathway has 
been identified for the AAR until now. Our observations are the first demonstration of an alternate, 
parallel pathway triggered by the accumulation of uncharged tRNA. The first part of my thesis reveals 
how conserved components of this stress response are, by demonstrating that core components of the 
mammalian ISR were already present over 550 million years ago in the common ancestor of cnidarians 
and bilaterians, playing a key role in stress adaptation not only in mammals but across metazoans. By 
looking at the conservation of the oldest part of the ISR, the AAR, evolutionary conservation helped us 
identify GCN1 as a mediator of an unidentified pathway induced by uncharged tRNA in mammalian cells 
observed by our lab.  GCN1 appears conserved throughout eukaryotes, suggesting it is at least as old as 
GCN2, suggesting the GCN2-independent GCN1 stress response pathway described here may be 
conserved throughout eukaryotes.  These observations as well as additional observations from the 
literature spanning eukaryotes, suggests the GCN2-independent GCN1 pathway mediates a conserved 
role in organismal defense. 
 
GCN1 senses the uncharged tRNA signal without GCN2  
The capacity of the signal initiating apparatus of the AAR to function in the absence of GCN2, strongly 
suggests that GCN1 or a complex containing GCN1 can recognize, bind and signal in response to 
uncharged tRNA.  In yeast, GCN1 is known to function at the ribosome and its ribosomal association is 
required for uncharged tRNA activation of GCN2 (6, 7).  This led to the model in yeast that GCN1 
detects the uncharged tRNA signal, either by direct binding of uncharged tRNA or by some other 
mechanism, at the ribosome (6, 8).  Data shown here suggests that mammalian GCN1 likewise binds the 
ribosome and that its ribosomal association is regulated by uncharged tRNA, suggesting mammalian 
GCN1 as in the yeast model detects the uncharged tRNA signal at the ribosome.  The most highly 
conserved part of GCN1 is the central portion of GCN1, which shows high similarity to eEF3, an ABC 
protein found only in yeast (8, 9).  Fungal eEF3 facilitates release of uncharged tRNA from the ribosomal 
E-site upon delivery of charged tRNA at the A-site during translation (8).  Although it is unknown if 
eEF3 directly binds uncharged tRNA, this similarity has been suggested to indicate that GCN1 plays a 
similar role with respect to uncharged tRNA at the ribosome.  In yeast, mutation of the eEF3-like domain 
of GCN1 impairs GCN2 activation more than expected from its effects on GCN1 ribosome binding alone, 
suggesting this domain has essential effector function in GCN2 activation by uncharged tRNA, possibly 
as a domain that binds uncharged tRNA, but this remains to be tested (7).  Rescue of knockdown or 
knockout GCN1 cells with various mutant GCN1 constructs could provide valuable insight into 
sequences important for GCN1 function.  Direct binding experiments could also be attempted but 
additional components could be required for GCN1 uncharged tRNA binding, which could lead to false 
negatives in in vitro binding assays; however, a positive result would be informative.  It is also possible 
that rather than acting as a direct binder of uncharged tRNA, GCN1 interacts with or scaffolds another 
currently unidentified uncharged tRNA sensor.  The TMT-MS interactomics described in chapter four 
will likely yield insight into these questions by identifying GCN1 interactors, which may function directly 
as uncharged tRNA sensors or form a complex required for GCN1 sensing of uncharged tRNA. 
 
Observations of GCN2-independence may represent observations of the GCN1 branch 
Whereas anecdotal literature has reported various cellular responses to amino acid limitation that occur 
without GCN2 from yeast to mammals, there has been no molecular explanation for these observations. 
The identified GCN1 branch could account for some of these observations.  In yeast, GCN2 independent 
splicing of ribosomal transcripts is induced by amino acid starvation within minutes (10). Transcriptional 
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profiling in mammals comparing wildtype and GCN2 null cells upon amino acid deprivation reveals a 
significant set of transcriptional changes that are independent of GCN2 (11).  Regulation of genes 
involved in amino acid biosynthetic pathways appeared largely dependent on GCN2, while amino acid 
regulation of genes involved in other processes such as cholesterol biosynthesis were independent of 
GCN2 (11).  Interpreting what specific molecular mechanisms are responsible for these effects are 
difficult, since amino acid deprivation stimulates multiple pathways including mTORC1.  Moreover, our 
data reveals that by treatment with an aaRS inhibitor, a large portion of transcriptional regulation by 
uncharged tRNA is in fact GCN2-independent.  Interestingly, our transcriptomic analyses suggested 
GCN2-independent GCN1-dependent genes were enriched in cholesterol biosynthetic processes as well.  
The existence of a novel GCN1 pathway will need to be considered in studies that have solely considered 
GCN2-dependence as a proxy for uncharged tRNA signaling in the cell.  In A. thaliana, a chemical 
known to prime the plant immune system and augment plant defense was found to bind to and inhibit 
activity of aspartyl-tRNA-synthetase (12).  Intriguingly, enhanced immunity by this chemical was 
independent of GCN2 (12).  It will be interesting to determine whether GCN2-independent effects in 
plants and yeast are likewise GCN1-dependent, which would indicate the GCN2-independent GCN1 
branch may be conserved throughout eukaryotes. 
 
The GCN1 branch may be a conserved protective uncharged tRNA signaling pathway 
Genetics in yeast, nematodes, and plants have suggested a role for GCN1 in a variety of regulatory events 
independent of GCN2, including responses to pathogens. Consideration of these genetic data in light of 
our findings points to a conserved role for a GCN1-dependent, GCN2-independent signaling downstream 
of amino acid limitation. Evidence for a functional role of GCN1 separate from GCN2 has been found in 
the nematode, C. elegans.  In C. elegans, GCN1 and ABCF3, physically interact, and are both required 
for apoptosis during development and in response to ionizing radiation, while GCN2 is not (13).  In yeast, 
GCN1 and GCN20 have genetic interactions distinct from GCN2 (14-16).  Further support for additional 
GCN1 functions come from the range of putative yeast and mammalian GCN1 protein interactors 
identified, which include a particularly high number of nuclear regulators, seemingly distinct from 
GCN1’s functional role with GCN2 (17-27).  Notably many studies across taxa have implicated GCN1 in 
organismal defense, but whether GCN2 also plays a role hasn’t been tested.  In the plant, A. thaliana, 
GCN1 is required for non-host and basal resistance against the bacteria, Pseudomonas syringae, and a 
separate study found both GCN1 and ABCF3 are required for bacteria-triggered stomatal closure (28, 29).  
Interestingly, GCN1 plays a role in plant cold response, and in mammals and yeast, translational 
inhibition that allows resistance to cold stress has been found to be independent of GCN2, peIF2α, and 
TOR (30).  In yeast and C. elegans GCN1 and GCN20/ABCF3 play roles in DNA damage (13, 31).  In 
mammals, the AAR has further evolved protective roles in the regulation of immunity (32-34). A central 
question that emerges with the identification of this new GCN1 pathway is how conserved is this novel 
branch, and if it is what are its roles. 
 
FUTURE DIRECTIONS 
 
Identification of GCN1 binding proteins 
How this new GCN1-dependent, GCN2-independent pathway mediates its effects remains unknown.  As 
described in this thesis we do know that GCN1 is involved upstream in the pathway and we have now 
identified a transcriptional program downstream of the pathway. Identification of GCN1 binding proteins 
will provide candidate mediators regulating the therapeutic transcriptional programs identified by 
transcriptomic analysis in chapter four.  HF treatment of cells in which identified proteins have been 
knocked down or knocked out with subsequent analysis of transcriptional changes by qPCR will begin to 
reveal what role these interactions play.  The identity of interacting proteins themselves may provide 
insight into further downstream mechanisms mediating transcriptional regulation.  Patterns discovered 
within the gene set regulated by this pathway identified by the trancriptomics will provide candidate 
transcriptional mediators that might be regulated by the pathway, which can then be further tested. 
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